

Chicago Fall Group Meeting



OCTOBER 8-10, 2026

Fall 2026: Taking Advantage of Every Opportunity

Welcome to SWOG's fall 2026 group meeting!

At the spring plenary in San Francisco, we laid out our vision for a SWOG research portfolio enriched with streamlined pragmatic trials that are high impact but easier for sites to conduct and enroll to – trials that ask and answer the vital questions industry won't.

Our plenary speakers at this Chicago meeting will help us get there.

On the cusp of a new NCORP grant cycle (we've just submitted our Research Base renewal application), we'll hear the NCI Community Oncology Research Program Director, Dr. Brandy Heckman-Stoddard, present on the vision for that program going forward.

From other plenary speakers, we'll get insights into the role of observational real-world evidence, perspectives from leaders of groundbreaking SWOG trials on how to implement pragmatic designs, and a close review of what "public powered" really means in the context of cancer clinical research.

Everywhere you go at the meeting, you'll learn of innovative new clinical trials.

Two of these trials will hold kickoff sessions: S2505, SWOG's first study in quite a few years focused solely on sarcoma, and S2419 BioFront, the first phase 3 trial anywhere to deploy a gut microbiome intervention as part of cancer treatment.

A number of others will be within a master protocol framework. Our Lung-MAP Update Forum, for example, will feature multiple innovative sub-studies – five currently open, several more in the works.

And the SWOG Clinical Trials Partnerships Update Forum will highlight brand new CTP-led trials – some recently opened, others approaching activation, all conducted without federal funding.

Of course, Group meetings are unique opportunities for networking and career development – not to mention for kicking back with colleagues. While you're in Chicago, we encourage you to take advantage of every opportunity!



A handwritten signature in black ink, appearing to read 'Dawn L. Hershman'.

Dawn L. Hershman, MD, MS
SWOG Group Chair



A handwritten signature in black ink, appearing to read 'Primo A. Lara Jr.'.

Primo "Lucky" N. Lara, Jr., MD
SWOG Group Chair

Group Meeting Index

Chair's Welcome Message	2
Schedule of Events	4-6
Top Accruals & Top Performing Sites	7-8
Plenary Session	9
Meeting Sponsors	10
Clinical Trials Partnerships (CTP) Update Forum	11
S2419 BioFront Kickoff	13
Frank & Linda Meyskens Annual Endowed Lectureship	14
Funding & Career Development Opportunities	14
S2505 Kickoff	16
Give to Support SWOG's Work	17
NCORP Research Base Clinical Trials Workshop	18
SWOG Committees	20
Adolescent and Young Adult Committee	21
Advanced Practice Provider & Nurse Scientist Committee	22-23
Lung-MAP Update Forum	24
Jeri & Noboru Oishi Symposium	25
Pharmaceutical Sciences & Drug Information Joint Meeting	26
SWOG Latin America Initiative Symposium	27
ORP Site Operations	28
Surgery Committee	29
Theranostics Subcommittee	30
Transplant and Cell Therapies Committee	31
VA Committee	32
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	33-36
Breast Committee	37-43
Cancer Control & Prevention Committee Leadership	44
Cancer Care Delivery Committee	45-46
Early Therapeutics & Rare Cancers Committee	57-61
Gastrointestinal Committee	62-72
Genitourinary Committee	73-85
Immunotherapeutics Committee	86-87
Leukemia Committee	88-92
Lung Committee	93-100
Lymphoma Committee	101-104
Melanoma Committee	105-107
Palliative Care Committee	47-48
Prevention, Screening, and Surveillance Committee	49-50
Radiation Oncology Committee	108
Symptom Management and Survivorship Committee	51-56
SWOG Publications	109-113
Future Meeting Dates	113

SWOG 2026 Fall Programs

Ballroom Level ■ | Concourse Level ■ | Lobby Level ■

FALL PROGRAM-AT-A-GLANCE

REGISTRATION & INFORMATION DESK:
REGENCY FOYER, BALLROOM LEVEL, WEST TOWER

WEDNESDAY: 3:00 PM - 6:00 PM

THURSDAY-FRIDAY: 6:30 AM - 5:00 PM

SATURDAY: 6:30 AM - 12:00 PM

HOPE FOUNDATION INFORMATION DESK:
REGENCY FOYER, BALLROOM LEVEL, WEST TOWER

THURSDAY-FRIDAY: 8:00 AM - 5:00 PM

SATURDAY: 8:00 AM - 11:00 AM



EXHIBITS
REGENCY FOYER, BALLROOM
LEVEL, WEST TOWER
THURSDAY-FRIDAY:
8:00 AM - 5:00 PM

▶ **GO TO THE MEETING APP ONLINE**
swog.org/meetingappF26

MEETING ROOM/LEVEL

WEDNESDAY, OCTOBER 7, 2026



4:00 PM–6:00 PM	Quality Initiative Meeting (Closed Business Meeting)	TORONTO ■
4:30 PM–6:00 PM	Hope Foundation Board Meeting (Hope Board Members Only)	SOLDIER FIELD ■
6:00 PM–8:30 PM	NCORP Research Base Executive Committee (Committee Members Only)	ACAPULCO ■

THURSDAY, OCTOBER 8, 2026

7:00 AM–8:30 AM	SWOG/COG AYA Joint Roundtable: NCORP (Invitation Only)	WRIGLEY ■
7:30 AM–8:00 AM	NCORP Research Base Clinical Trials Workshop Check-In	REGENCY D FOYER ■

7:30 AM–8:30 AM	Professional Integrity & Member Engagement (PRIME) Council (Committee Members Only)	SAN FRANCISCO ■
8:00 AM–11:00 AM	SWOG NCORP Research Base Clinical Trials Workshop	REGENCY D ■
8:30 AM–10:30 AM	Advocates Committee (Committee Members Only)	ACAPULCO ■
9:00 AM–10:30 AM	SWOG Latin America Initiative Symposium	REGENCY A ■
11:00 AM–1:30 PM	Early Therapeutics and Rare Cancers Committee	REGENCY C ■
11:30 AM–1:30 PM	Cancer Care Delivery Committee	REGENCY A ■
12:00 PM–2:00 PM	Lymphoma Working Group (Working Group Members Only)	ACAPULCO ■
1:00 PM–2:30 PM	Site Operations	REGENCY D ■
2:00 PM–3:00 PM	S2505 Kick Off Meeting	WATER TOWER ■
2:00 PM–3:30 PM	SWOG Tissue Banking Meeting (Closed Business Meeting)	GOLD COAST ■
2:00 PM–3:30 PM	Transplant & Cell Therapies Committee	COMISKEY ■
2:00 PM–4:00 PM	Prevention, Screening, and Surveillance Committee	REGENCY A ■
2:00 PM–4:00 PM	Lung Radiation/Surgery Subcommittee (Committee Members Only)	SAN FRANCISCO ■
2:30 PM–3:30 PM	Clinical Trials Partnerships Update Forum	REGENCY C ■
2:30 PM–4:00 PM	Professional Review Committee (Closed Business Meeting)	SOLDIER FIELD ■
2:30 PM–4:30 PM	Recruitment & Retention Committee (Closed Business Meeting)	WRIGLEY ■

SWOG 2026 Fall Programs

Ballroom Level ■ | **Concourse Level** ■ | **Lobby Level** ■

3:45 PM–5:45 PM	Sarcoma Working Group of the Early Therapeutics Committee	GOLD COAST ■
4:00 PM–6:00 PM	Radiation Oncology Cmte	COMISKEY ■
4:00 PM–7:00 PM	Lung Working Group (Working Group Members Only)	TORONTO ■
4:30 PM–6:30 PM	Symptom Management and Survivorship Committee	REGENCY A ■
5:00 PM–6:00 PM	Conflict Management Committee (Closed Business Meeting)	SOLDIER FIELD ■
5:00 PM–6:30 PM	VA Committee	WATER TOWER ■
5:00 PM–7:00 PM	Lymphoma Committee	REGENCY C ■
6:00 PM–7:30 PM	Early Therapeutics & Rare Cancers Working Group (Invitation Only)	ACAPULCO ■
6:15 PM–7:15 PM	Theranostics Subcommittee	COMISKEY ■
7:00 PM–9:00 PM	SWOG/COG AYA Joint Roundtable: Disease-Specific (Invitation Only)	WRIGLEY ■

FRIDAY, OCTOBER 9, 2026

7:00 AM–8:00 AM	NCORP/MU-NCORP Site PI Meeting	WATER TOWER ■
7:00 AM–8:00 AM	Lung-MAP Admin Meeting (Committee Members Only)	ACAPULCO ■
7:00 AM–8:30 AM	Imaging Committee (Committee Members Only)	SAN FRANCISCO ■
7:00 AM–11:00 AM	GU Working Group (Committee Members Only)	REGENCY D ■
7:15 AM–8:15 AM	CTP Scientific Advisory Board (Closed Business Meeting)	SOLDIER FIELD ■
7:30 AM–10:30 AM	SWOG Data & Safety Monitoring Committee (Closed Business Meeting)	GOLD COAST ■
8:00 AM–9:30 AM	Surgery Committee	COMISKEY ■

8:00 AM–10:00 AM	Palliative Care Committee	REGENCY A ■
8:15 AM–9:45 AM	Lung-MAP Site Coordinators Meeting (Committee Members Only)	ACAPULCO ■
8:30 AM–9:00 AM	Jeri & Noboru Oishi Symposium Check-In	REGENCY B FOYER ■
8:30 AM–12:00 PM	Breast Committee & TM Working Group (Working Group Members Only)	TORONTO ■
9:00 AM–10:00 AM	Lung Community Engagement Subcommittee (Committee Members Only)	SAN FRANCISCO ■
9:00 AM–11:00 AM	Immunotherapeutics Committee	WATER TOWER ■
9:00 AM–11:30 AM	Jeri & Noboru Oishi Symposium	REGENCY BC ■
9:15 AM–11:15 AM	Pharmaceutical Sciences Committee & Drug Information Subcommittee	SOLDIER FIELD ■
10:00 AM–11:15 AM	Metastatic Lung Cancer Subcommittee (Committee Members Only)	HAYMARKET ■
10:00 AM–1:30 PM	GI Committee & TM Working Group (Working Group Members Only)	CRYSTAL C ■
10:30 AM–12:30 PM	Leukemia Working Group (Working Group Members Only)	ACAPULCO ■
11:30 AM–1:00 PM	Adolescent & Young Adult (AYA) Committee	WATER TOWER ■
11:30 AM–1:30 PM	Lung Committee	REGENCY A ■
11:45 AM–1:45 PM	Advanced Practice Prov & Nurse Scientists Committee	COMISKEY ■
12:00 PM–1:30 PM	Oncology Research Professionals (ORP) Open Forum	CRYSTAL B ■
1:00 PM–1:30 PM	Publications Committee (Closed Business Meeting)	GOLD COAST ■

SWOG 2026 Fall Programs

Ballroom Level ■ | Concourse Level ■ | Lobby Level ■

FALL PROGRAM-AT-A-GLANCE

1:00 PM–2:00 PM	Plenary Reception	REGENCY FOYER ■
2:00 PM–4:00 PM	Plenary Session	REGENCY B-D ■
4:15 PM–5:15 PM	S2419 (Biofront) Kick Off Meeting	COMISKEY ■
4:15 PM–5:45 PM	LungMAP Update Forum	CRYSTAL A ■
4:15 PM–6:15 PM	Breast Committee	REGENCY A ■
4:30 PM–6:30 PM	GI Committee	CRYSTAL C ■
4:30 PM–6:30 PM	Leukemia Committee	WATER TOWER ■
6:45 PM–8:30 PM	Group Reception	REGENCY BC ■

SATURDAY, OCTOBER 10, 2026

7:00 AM–7:45 AM	Board of Governors (Board Members Only)	REGENCY D ■
8:00 AM–9:00 AM	Committee Chairs (Committee Chairs Only)	REGENCY D ■
8:00 AM–10:00 AM	Mentoring APPs (Invitation Only)	GOLD COAST ■
9:15 AM–10:45 AM	Quality Assurance Committee (Committee Members Only)	SAN FRANCISCO ■
9:15 AM–11:15 AM	Melanoma Working Group (Working Group Members Only)	COMISKEY ■
9:15 AM–11:15 AM	GU Committee	REGENCY A ■
9:15 AM–11:15 AM	Myeloma Working Group (Working Group Members Only)	ACAPULCO ■
9:30 AM–11:30 AM	CTP Strategic Retreat (Invitation Only)	SOLDIER FIELD ■
11:30 AM–1:30 PM	Melanoma Committee	REGENCY D ■
11:30 AM–1:30 PM	Barlogie-Salmon Myeloma Committee	COMISKEY ■

MAKE A WILL, MAKE A WAY

The Hope Foundation has a partnership with FreeWill, an easy online resource that more than 100 Hope supporters in 12 different states have used to create their wills and leave a gift to Hope. You can make a will in as little as 20 minutes, at no cost, and get peace of mind for the future.



SCAN THE QR CODE BELOW TO CREATE A LEGACY
WITH THE CAUSES YOU CARE ABOUT MOST.

THE HOPE
FOUNDATION
FOR CANCER RESEARCH
FREEWILL



Visit The Hope Foundation table
near registration to learn more



Our Top Performing Sites

To help our data management sites track their performance relative to that of others, we have developed a metric based on the quality and timeliness of data and biospecimen submissions. Data management institutions with at least 10 SWOG accruals in the prior 13 months are scored on this scale.

The members below are SWOG's top-performing sites for the period of January 1, 2026 through June 30, 2026

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Our Lady of the Lake Hospital

Ohio State University Comprehensive Cancer Center

Rhode Island Hospital

NCORP of the Carolinas (Prisma Health NCORP)

Upstate Carolina Consortium Community Oncology Research Program

Sutter Cancer Research Consortium

Lahey Clinic

Banner University Medical Center – Tucson

Huntsman Cancer Institute/University of Utah

Cancer Research for the Ozarks NCORP

STCC at DHR Health Institute for Research and Development

THANKS TO

Our Top Accruers

Patient volunteers power our trials —
and SWOG members connect us to them.

SWOG-Credited Registrations to SWOG-Managed Trials
January 1, 2026 through June 30, 2026



Regents of the
University of Michigan

University of Rochester LAPS

Instituto Nacional
De Cancerologia de Mexico

University of Texas MD Anderson
Cancer Center LAPS

STCC at DHR Health Institute
for Research and Development

University of Arkansas
for Medical Sciences



Southeast Clinical Oncology
Research Consortium NCORP

Michigan Cancer Research
Consortium NCORP

Heartland Cancer Research NCORP

Cancer Research of Wisconsin and
Northern Michigan Consortium

The University of Kansas Cancer
Centers-MCA Rural NCORP

Kaiser Permanente NCI Community
Oncology Research Program



Plenary Session

Fall 2026 SWOG Group Meeting

2 - 4 pm CT, Friday, October 9, 2026 Hyatt Regency Chicago and online

SWOG and the NCI: Advancing the Research Cooperative Groups Do Best (Part I)



SWOG Updates and Transitions

Dawn L. Hershman, MD, MS, and Primo N. (Lucky) Lara, Jr., MD
Group Chairs, SWOG Cancer Research Network



Vision for NCORP as We Approach a New Grant Cycle
Brandy Heckman-Stoddard, PhD, MPH
*Director, NCI Community Oncology Research Program
Division of Cancer Prevention,
National Cancer Institute*



The Role of Federally Sponsored Clinical Trials in Cancer Research
Joseph M. Unger, PhD
*SWOG Statistics and Data Management Center
Professor, Public Health Sciences Division,
Fred Hutch Cancer Center*



Can Observational Real World Evidence Replace Randomized Clinical Trials?
Steven Piantadosi, MD, PhD
*Director, Data Innovation Lab & Associate
Group Chair for Strategic Initiatives
and Innovation
Alliance for Clinical Trials in Oncology*



Pragmatic Trials in Oncology: Lessons from TrACER (S1415CD)
Scott Ramsey, MD, PhD
*Director, Hutchinson Institute
for Cancer Outcomes Research
Fred Hutch Cancer Center*



Pragmatic Trials in Oncology: Lessons from Pragmatica-Lung (S2302)
Karen Reckamp, MD
*Director, Division of Medical Oncology
Professor, Department of Medicine
Cedars-Sinai Health Sciences University*



Statistical Considerations for the Design of Pragmatic Trials
Mary W. Redman, PhD
*SWOG Statistics and Data Management Center
Professor, Clinical Research Division,
Fred Hutch Cancer Center*

Panel Discussion

*Moderators: Dawn L. Hershman, MD, MS,
and Primo N. (Lucky) Lara, Jr., MD
All Presenters*



The Hope Foundation thanks Bronze Meeting Sponsors



2026-27 Corporate Members



THE HOPE
FOUNDATION
FOR CANCER RESEARCH

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, OCTOBER 8 • 2:30 - 3:30 PM CT • REGENCY C (BALLROOM LEVEL, WEST TOWER) & ONLINE

SWOG CTP overview

- Joint study development process
- Scientific areas of interest
- Types of trials

SWOG CTP active trials

- **26CTP.LEUK02 (APEX-MF)**: A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib for Treatment-Naïve, Cytopenic Myelofibrosis
- **21CTP.LEUK01**: Phase II Trial for Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia
- **21CTP.HN01 (CAPT-HN)**: A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer



To apply to open a study, complete its feasibility survey at swogctp.org/trials.

SWOG CTP closed trials

- TROPION Breast 03 FDA registration trial – accrual completed, in follow-up

SWOG CTP trials in development

- **21CTP.BREAST01 (MONITOR)**: Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, HER2-negative Metastatic Breast Cancer
- **26CTP.BMT01**: HA-1 TCR T-cell phase II treatment trial

Site logistics

- Site selection, activation, and engagement
- Site funding and contracts

Novel CTP projects and other collaborative opportunities

Learn more: swogctp.org

All are invited!

Email us: CTP@swog.org

For a one-on-one appointment with our Research Site Coordination Manager: sitecoordination@swogctp.org

National Estate Planning Awareness Week

October 19-25

In 2008, the US House of Representatives passed a resolution designating the third week of October as National Estate Planning Awareness Week (NEPAW).

Because:

120M+ Americans lack an up-to-date estate plan

Many are unaware of the importance of planning

Raising awareness helps families secure their financial futures

The Hope Foundation partners with Freewill to offer free estate planning education and services to SWOG members and supporters.

Visit us near SWOG registration to learn more about creating a legacy with the causes you care about most!

THE HOPE
FOUNDATION
FOR CANCER RESEARCH

FREEWILL 

S2419 BioFront Kickoff:

Adding a Biotherapeutic to Immunotherapy for Advanced Renal Cell Carcinoma

FRIDAY, OCT 9 • 4:15 – 5:15 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER) & ONLINE

S2419: Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)



S2419 asks if modulating the gut microbiome can enhance immune checkpoint inhibitor efficacy in patients with advanced clear cell renal cell carcinoma.



S2419 was designed to be easy to open and enroll to, across all types of treatment sites. Its intervention is a once-daily capsule requiring no refrigeration or special handling.

The kickoff will provide information on the trial's scientific rationale and study design • key eligibility and treatment details

- correlative science components • biospecimen collection
- safety monitoring • quality-of-life objectives • accrual strategies


S2419 activated in April 2026. Its enrollment goal is 718 patients.

Attend the S2419 BioFront Kickoff. Bring your questions for the study team.

All NCTN and NCORP investigators and research staff are invited.

Hybrid session: Attend IN-PERSON or ONLINE

PRESENTERS



Pedro C. Barata,
MD, MSc
Study Chair




Ulka
Vaishampayan,
MD
Study Co-Chair



Monty Pal, MD
Study Co-Chair



Laura Esfeller,
MA
GU Renal
Subcommittee
Patient Advocate



Nazli Dizman,
MD
TM Co-Chair

THE FRANK AND LINDA MEYSKENS ANNUAL ENDOWED LECTURESHIP ON ADVANCES IN CANCER PREVENTION

“The NCI Cancer Prevention Clinical Trials Network (CP-CTNet) Program and Portfolio of Clinical Trials”



by **Goli Samimi, PhD, MPH**

Director, Cancer Prevention Clinical Trials Network (CP-CTNet)
Division of Cancer Prevention, National Cancer Institute

**Presented within the Prevention, Screening,
and Surveillance Committee session**

Thursday, October 8 • 2 – 4 pm CT • Regency A (Ballroom Level, West Tower)

Since the early 1980's, Dr. Frank Meyskens has been a leader in the recognition, development, and clinical usage of prevention in the management of cancer. Frank and Linda have directed the development of this lectureship to advance the explosion of knowledge that is expanding opportunities to engage prevention in personalized medicine, including early detection and genetically focused treatment options.

Upcoming Funding & Career Development Opportunities

- CRA/Nurse Travel Support: **January 15**
- VA Staff Travel Support: **January 15**
 - Impact Award LOIs: **January 15**
- Vogelzang Scholars Program: **January 15**
 - Secondary Data Analysis: **Rolling**
 - SWOG Trial Support: **Rolling**

thehopefoundation.org/programs

THE **HOPE**
FOUNDATION
FOR CANCER RESEARCH

Support SWOG through your Donor-Advised Fund (DAF)

Why a DAF?



Tax efficiency, timed to your benefit. Contribute when the timing is right for you. Grant when the timing is right for the cause.



Simplicity and flexibility. Organize your giving – one account, one tax receipt, unlimited generosity.

Questions? Stop by The Hope Foundation info table near meeting registration!

Run Austin or Orange County. Advance SWOG Research.

**THE HOPE
FOUNDATION**
FOR CANCER RESEARCH

The Hope Foundation has partnered to engage runners with the 2027 marathons in Austin and Orange County! Raise awareness and funding for SWOG. Whether a marathon is a bucket-list goal you've been contemplating or a part of your regular running practice, we'd love to help you get there with a Hope-sponsored bib!

Visit us at The Hope Foundation table near registration to learn more.

S2505 Kickoff: Non-Inferiority of Short-Course RT for Soft-Tissue Sarcoma

THURSDAY, OCT 8 • 2 – 3 PM CT • WATER TOWER (CONCOURSE LEVEL, WEST TOWER) & ONLINE

S2505: Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-III B, Extremity, Resectable Soft Tissue Sarcoma

S2505 is the first randomized head-to-head study comparing standard to hypofractionated radiation in this setting.

Primary endpoint: non-inferior local tumor recurrence at 2 years

Shorter radiotherapy before surgery could reduce patients' time to surgery, lower costs, and enhance quality of life.

The kickoff will offer information and practical guidance on

- key trial components • eligibility criteria • treatment flow
- submission of radiation treatment plans and real-time quality assurance
 - how to complete required training on tumor contouring
 - optional biospecimen banking

S2505 activated earlier this summer and has an enrollment goal of 296 patients.


PRESENTERS:

Attend the S2505 Kickoff

- ✓ Bring your questions for a Q&A with the study team.
- ✓ All NCTN and NCORP investigators and staff are invited.
- ✓ Hybrid session: IN-PERSON & VIRTUAL attendance options



*Jeremy Harris,
MD, MPhil*



*Alejandro
Hernandez, MS*

Give to Support the Very Best Science

Your generosity helps research teams and patients.

Thank you for making a difference through your work with SWOG.

Today, take your passion for research a step further by making a gift, starting a monthly donation, or planning a future contribution through The Hope Foundation, SWOG's public charity. Your generosity sustains high-quality, patient-centric clinical research.

thehopefoundation.org/donate

Or visit our table near registration to give today!



**THE HOPE
FOUNDATION**
FOR CANCER RESEARCH

12th Annual NCORP Research Base Clinical Trials Workshop

THURSDAY, OCT 8 • 8 – 11 AM CT • REGENCY D (BALLROOM LEVEL, WEST TOWER)

(CHECK-IN BEGINS 7:30 AM)

Open to site staff and investigators at all sites (not just NCORP sites), the workshop centers on general interest areas related to conducting clinical trials in the SWOG NCORP Research Base committees in Cancer Care Delivery; Palliative Care; Prevention, Screening, & Surveillance; and Symptom Management & Survivorship

General Session: 8:00 to ~9:30 am, in-person & online

General Clinical Trial topics include:

Drug Costs in Federally Sponsored Cancer Clinical Trials



Joseph Unger, PhD

Patient Reported Outcomes in SWOG Clinical Trials



Katie Arnold, MS

NCI Cancer Care Delivery Research (CCDR) Update



Ashley Buscetta, MSN, FNP-BC, CWOCN

Clinical Trials Perspectives will focus on Participant Trust and Clinical Trials:

What Are We Asking Patients to Trust? Lessons from the Institutional Medical Mistrust Scale



Marilyn Baffoe-Bonnie, PHD, MBE

Words Matter: How Plain Language Can Help You Build Trust with Patients and Successfully Communicate Your Message



Andrea Mongler, MPH

We will also hear from a SWOG Patient Advocate



Marielle McLeod, MHA, CPN

Breakout Discussion Sessions:

9:30 – 11:00 am, in-person only

Informal discussion sessions are for information-sharing amongst attendees and facilitators. We invite all to come and share your ideas and strategies for conducting studies.

- Patient-Reported Outcomes
- Trust and Communication
- Study-specific sessions on Cancer Care Delivery studies S2417CD and S2424CD



All are invited!

Sponsored by The Hope Foundation for Cancer Research

THE HOPE FOUNDATION
FOR CANCER RESEARCH

SOCRA

Society of Clinical Research Associates (SOCRA) continuing education credit is available.

SWOG Group Meeting App

The SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 create your schedule, annotate sessions, and add them to your calendar

3 access zoom links for hybrid sessions

2 access a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

- find travel and lodging information and links
- view speaker guidelines, update photo and bio

4 access individual meeting agendas

5 access the full agenda book itself as a PDF



swog.org/appleappF26



swog.org/googleappF26

DON'T HAVE THE APP YET?

Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?

Access the web browser version with the QR code or URL at right.



swog.org/meetingappF26



Committees

Disease & Research Committees

- Breast:** Lajos Pusztai, MD, DPhil
- Cancer Care Delivery:** Scott Ramsey, MD, PhD & Veena Shankaran, MD
- Early Therapeutics & Rare Cancers:** Razelle Kurzrock, MD
- Gastrointestinal:** Philip Philip, MD, PhD
- Genitourinary:** Seth Lerner, MD
- Leukemia:** Harry Erba, MD, PhD
- Lung:** Jhanelle Gray, MD
- Lymphoma:** Sonali Smith, MD
- Melanoma:** Sapna Patel, MD
- Myeloma:** Amrita Krishnan, MD
- Palliative Care:** Robert Krouse, MD & Marie Bakitas, PhD
- Prevention, Screening, & Surveillance:** Banu Arun, MD & Jason Zell, DO
- Symptom Management & Survivorship:** Norah Lynn Henry, MD, PhD & Michael Fisch, MD

Modality Committees

- Imaging:** Lawrence Schwartz, MD
- Immunotherapeutics:** Katerina Politi, PhD & Siwen Hu-Lieskovan, MD, PhD
- Radiation Oncology:** Chul Soo Ha, MD
- Surgery:** Syed Ahmad, MD
- Transplant & Cell Therapies:** Patrick Hagen, MD

Research Support Committees

- Adolescents & Young Adults:** Rebecca Johnson, MD
- Advanced Practice Providers:** Christa Braun-Inglis, DNP, APRN & Jamie Myers, PhD, RN
- Oncology Research Professionals:** Connie Szczepanek, RN, BSN
- Patient Advocates:** Barbara Segarra-Vazquez, DHSc & Anne Marie Mercurio, PA
- Pharmaceutical Sciences:** Joyce Lee, PharmD
- Recruitment & Retention:** Allison Caban-Holt, PhD
- Veterans Affairs:** Stephen Bartlett, RPh, MSPH

Administrative Committees

- Board of Governors:** Dawn Hershman, MD, MS & Primo Lara, Jr., MD
- Conflict Management:** Paul Okunieff, MD
- Professional Review Committee:** Paul Hesketh, MD
- Publications:** David Horowitz, MD

Adolescent and Young Adult Committee

FRIDAY, OCTOBER 9 • 11:30 AM – 1:00 PM CT • WATER TOWER (CONCOURSE LEVEL, WEST TOWER)

Agenda

- A. Welcome**
Becky Johnson, MD
- B. AO92204: Testing the Addition of Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer**
Allison O'Neill, MD
- C. AYA Melanoma Updates**
Leah Winer, MD
- D. AYA Colon Cancer Updates**
Chris Cann, MD
- E. S1823: Results of A Prospective Observational Cohort Study to Assess miRNA37 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors**
Lucia Nappi, MD, PhD
- F. ALTE-2131: Triptorelin and protection of ovarian reserve in AYAs with cancer**
Becky Johnson, MD
- G. Implementing financial hardship and health-related social needs screening in outpatient AYA oncology**
Melissa Beauchemin, PhD
- H. Patient Advocacy Updates**
Allison Rosen (Virtual)
- I. Q&A and discussion**

Advanced Practice Provider and Nurse Scientist Committee

FRIDAY, OCTOBER 9 • 11:45 AM - 1:45 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

GENERAL ITEMS

Introductions: Welcome to all our first time SWOG attendees and new members
Christa Braun-Inglis, DNP, APRN

Review plans for metrics collection
Jamie Myers, PhD, RN, AOCNS, FAAN

Update on NCORP Executive Committee Meeting
Jamie Myers, PhD, RN, AOCNS, FAAN

Update on practice patterns measurement/metrics for impact of DCP and CTEP APP policy/guidelines effective
Ashley Buscetta, MS, NP, NCI

Committee membership

PROTOCOL SUPPORT

Highlighted SWOG studies for APP Trial Support and Championship

Protocol Review Subgroup: Solid Tumor, Hematologic
Christa Braun-Inglis, DNP, APRN

APP Liaisons
GI Committee: Arlene Ortega, NP-C, AOCNP
Others in progress

Initial Order Build (IOB) Subgroup
Joyce Lee, PharmD, BCOP, BCPS

continued on next page

Advanced Practice Provider and Nurse Scientist Committee

FRIDAY, OCTOBER 9 • 11:45 AM - 1:45 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Nurse Supported Trials in Progress:

S2416 TRACE Study (PI Greenlee) - Kuulei Fahling, ARNP, Nurse Coordinator

S2418 Family/STRONG (PI Odom) - Helene Rider, RN, Nurse Coordinator

S2205 STOP CIPN (PI Accordino) - Stephanie Reyes, MSN, RN, OCN, Nurse Coordinator

NRG-CC011 Computerized Cognitive Training (PI Von Ah) - Jamie Myers, SWOG Champion

EDUCATION AND MENTORSHIP

MAPP Program - Diane Barber, PhD, APRN, ANP-BC, AOCNP, FAANP, FAAN and Christa Braun-Inglis, DNP, APRN

WF-2403 COACH - Christa Braun-Inglis, DNP, APRN

APP Clinical Research Course Development-collaboration with APSHO
Christa Braun-Inglis, DNP, APRN

Concept Corner - Jamie Myers, PhD, RN, AOCNS, FAAN

R-25 at City of Hope - Early Phase Trials for Palliative Care Education - Christa Braun-Inglis, DNP, APRN and Marie Bakitas, RN, DNSc, FAAN, FPCN

Publications/Presentations - Christa Braun-Inglis, DNP, APRN

OPEN FORUM

Next Meeting Dates:

1. Monthly meetings - Third Mondays at noon Pacific, 1:00 Mountain, 2:00 Central, 3:00 Eastern

2. Spring meeting, April 16, 2027, 11:30 - 1:30 PT, San Francisco

Lung-MAP Update Forum

FRIDAY, OCTOBER 9 • 4:15 - 5:45 PM CT • CRYSTAL A (LOBBY LEVEL, WEST TOWER)

Agenda

Welcome and Introductions	Karen Reckamp, Saiama Waqar	4:15 p.m.
Lung-MAP Accomplishments	Karen Reckamp	4:20 p.m.
Lung-MAP Retreat Summary	Saiama Waqar	4:30 p.m.
Manuscript and Accrual Updates	Mary W. Redman	4:40 p.m.
Presentation: Association Between Grade of irAEs and Outcomes	Christina Baik	4:45 p.m.
<i>Active Study Updates</i>		
S1800E	Saiama Waqar	4:55 p.m.
S1900G	Sarah Goldberg	5:00 p.m.
S1900J	Christian Rolfo	5:05 p.m.
S1900K	Paul K. Paik	5:10 p.m.
S1900N	John Wrangle	5:15 p.m.
Q & A	Karen Reckamp	5:20 p.m.
<i>Developing Study Updates</i>		
S1900P	Paul K. Paik	5:25 p.m.
S1900Q	Konstantin Dragnev	5:30 p.m.
<i>Open Forum</i>		
Q & A	Karen Reckamp, Saiama Waqar, Mary W. Redman	5:35 p.m.

ORP Jeri & Noboru Oishi Symposium

FRIDAY, OCTOBER 9 • 9:00 – 11:30 AM CT • REGENCY BC (BALLROOM LEVEL, WEST TOWER)

<i>Time</i>	<i>Topic</i>	<i>Speaker</i>
9:00 – 9:10 am	Opening Remarks & Announcements	Connie Szczepanek, RN, BSN Joyce Nancarrow Tull, RN, MSN
9:10 – 9:55 am	Medically Necessary. Standard of Care. Covered? Not Necessarily.	Denise Quint, CPC, CHC, CHRC Denise Quint LLC "What Research Teams Need to Know About Clinical Trial Billing"
9:55 – 10:25 am	Quality Assurance Updates	Laura Gonzales, RN, BSN; SWOG Cancer Research Network Quality Assurance Manager
10:25 – 11:20 am	FDA Focus & Updates	Jennifer Adams, BS, MPH Commander, US Public Health Service Branch Chief, Bioresearch Monitoring Foreign Investigation Branch, U. S. Food & Drug Administration
11:20 – 11:30 am	Q & A	Jennifer Adams, BS, MPH; Branch Chief Colleen E. Burke, RN, MSN; FDA Investigator

PLEASE KEEP THIS AGENDA AND USE THE FILLABLE STATEMENT BELOW TO DOCUMENT YOUR EDUCATIONAL CREDITS.

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to my education and professional advancement in clinical research.

Signature _____ Date _____

Oishi Education Sub-Committee Co-Chairs:

Kira Pavlik, MPH, CCRP – kira.pavlik@yale.edu

Joyce Nancarrow Tull, MSN, RN – jtull@health.ucsd.edu

Pharmaceutical Sciences Committee and Drug Information Subcommittee Joint Meeting

FRIDAY, OCTOBER 9 • 9:15 – 11:15 AM CT • SOLDIER FIELD (CONCOURSE LEVEL, WEST TOWER)

Agenda

1. ***Committee Administrative reports – Joyce Lee***
 - Membership updates
 - Review of PSC member roster
 - Summary of committee activities
2. ***Drug Information Subcommittee – Vy Bui***
 - Subcommittee updates
 - Workload Summary: Drug Information section requests
 - Introduction of resident/fellow writers for 2026-2027 academic year
3. ***APP Initial Order Build (IOB) Focus Group – Siu Fun Wong/Joyce Lee***
 - Program development updates
4. ***Protocol review activities – Jorge Avila/Joyce Lee***
 - Protocol review updates: current and upcoming protocol review activities
5. ***NCI Aurora rollout updates – Matt Boron***
6. ***Pharmacist Liaison Report***
 - Review of Pharmacist Liaison assignment list
 - Pharmacist Liaison reports
 - Open discussion
7. ***Open agenda – All***
 - Additional topics and discussion

SWOG Latin America Initiative Symposium

THURSDAY, OCTOBER 8 • 9:00 – 10:30 AM CT • REGENCY A (BALLROOM LEVEL, WEST TOWER)

Agenda

Welcome, *Dr. Mariana Chávez Mac Gregor*

Session Moderators: *Drs. Irene Tamí-Maury and Iván Lyra-González*

Facilitation of discussion and audience Q&A throughout the symposium

Part 1: Rare Cancers: Opportunities and Challenges for SWOG and Latin America

*The sarcoma working group in the early therapeutics and rare cancers committee, **Dr. Lara Davis***

*Rare cancer epidemiology and opportunities for research in Latin America, **Dr. Iván Lyra-González***

*Challenges in conducting trials in rare tumors: Lessons from DART, **Dr. Megan Othus***

Part 2: Round Table Discussion about Collaborations

*Collaboration opportunities: S2505 and beyond, **Drs. Jeremy Harris and Natalia Jara***

Part 3: Site Site Focus: SLAI Activities and Rare Cancer Overview by Country

*Focus: Uruguay, **Dr. Mauricio Cuello/Dr. Iván Lyra-González***

*SLAI activities and rare cancer patient overview by country, **all SLAI sites***

Closing Remarks, *Dr. Mariana Chávez Mac Gregor*

SWOG Site Operations Meeting Agenda

THURSDAY, OCTOBER 8 • 1:00 - 2:30 PM CT • REGENCY D (BALLROOM LEVEL, WEST TOWER)

Agenda

<i>Open, Welcome, and Announcements</i>		<i>Site Operations Committee</i>
<i>General Updates</i>		
<i>National Cancer Institute (NCI)</i>		<i>Grace Mishkin</i>
<i>Clinical Trials Support Unit (CTSU)</i>		<i>James Wise</i>
<i>SWOG Updates</i>		
<i>SWOG Network Operations Center</i>	<i>Administration & Study Funding</i>	<i>Pat Mize & Casey Dawson</i>
	<i>Quality Assurance (QA)</i>	<i>Laura Gonzales</i>
	<i>Information Systems</i>	<i>Cara Laubach</i>
<i>Statistics & Data Management Center (SDMC)</i>		<i>Kari Chansky</i>
<i>Closing Remarks</i>		<i>Site Operations Committee</i>

Surgery Committee

FRIDAY, OCTOBER 9 • 8:00 – 9:30 AM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

Update from Executive Officer

Lisa A. Kachnic, MD, FASTRO, Chair, Radiation Oncology, Columbia University

Update on Clinical Trials Targeting KRAS (Virtual Presentation)

Wungki Park, MD, Assistant Attending Physician, Hepatopancreaticobiliary Section
Gastrointestinal Oncology Section, Memorial Sloan Kettering Cancer Center, New York NY

Trials and Projects in Development and Ongoing Trials

An Update on S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula.

Jonathan Sham, MD, University of Washington, Seattle WA

An Update on S2605: A Phase III Trial of Preoperative Chemotherapy vs Surgery First (CRS-HIPEC) for High-Grade Appendiceal Cancer.

Sameer Patel, MD, University of Cincinnati, Cincinnati OH

SWOG 2703: Randomized Phase II Trial of Neoadjuvant Dostarlimab Versus Post-Operative Standard Pathway of Adjuvant FOLFOX/ CAPOX Plus Atezolizumab for Localized MSI-H/dMMR Colon Cancer

Emerson Y. Chen, MD, MCR, Knight Cancer Institute, Oregon Health and Science University

VANGUARD: Value of Adjuvant Non-cross-resistant therapy in Gastroesophageal cancer Using an Antibody-drug conjugate for Residual Disease

Raghan Sundar, MD, PhD and Christopher Rodman, MD, Yale School of Medicine and Yale Cancer Center, New Haven CT

Chemotherapy with or without HAIP for unresectable liver only intrahepatic cholangiocarcinoma

Ronan Hsieh, MD, Washington State University College of Medicine and Swedish Cancer Institute, Seattle WA

Theranostics Subcommittee

THURSDAY, OCTOBER 8 • 6:15 – 7:15 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

6:00 - 6:05 pm	Welcome	Jeffrey Wong, MD Tanya Dorff, MD Jeremie Calais, MD, PhD
6:05 - 6:20 pm	Update from IROC	Michael Knopp, MD, PhD
6:25 - 6:45 pm	Dosimetry-Guided ¹⁷⁷Lu-PSMA-617 Treatment for mCRPC	Ravi Patel, MD, PhD
6:50 - 7:10 pm	Phase 2 Randomized Trial of Lu177+SBRT vs. ARPI+Lu177+SBRT for mHSPC (virtual)	Adeel Kaiser, MD
7:10 pm	Future Speakers and Closing Remarks	Jeffrey Wong, MD

November 6, 2026

Pentixapharm, Inc.
Radiolabeled CXCR4-targeting compounds, PentixaTher and PentixaFor- imaging and therapy of hematopoietic malignancies

Disease Sites of interest

Acute leukemia
BMT conditioning acute leukemia undergoing allo-HCT
Multiple Myeloma
Lymphoma

December 4, 2026

Pentixapharm, Inc.
GT-008 is a CD24-targeting mAb- theranostic agent in female cancers (breast, ovarian).

Disease Sites of Interest

Breast
Ovarian / GYN

Transplant and Cell Therapies Committee

THURSDAY, OCTOBER 8 • 2:00 – 3:30 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

1. Pending Studies

- a. *A Phase II Randomized Study Comparing Total Marrow and Lymphoid Irradiation (TMLI) with Fractionated Total Body Irradiation (FTBI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) in Patients with Acute Lymphoblastic Leukemia – Dr. Monzr M Al Malki and Dr. Jeffrey Wong*
- b. *EA 4241: A Two Cohort Randomized Study for Patients with High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse – Dr. Sairah Ahmed*

2. Active Protocol Updates

- a. *SWOG 2213: Phase 3 randomized trial of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D-VCD) induction followed by autologous stem cell transplant or D-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis – Dr. Patrick Hagen*
- b. *SWOG 2114: A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma - Dr. Brian Hess*
- c. *EA 4232: PTCL-STAT (Stem-cell Transplant AuTologous) - Dr. Marc Hoffmann*
- d. *MyeloMatch Update: MM3TCT-A03: A Two Cohort, Randomized, Open-Label, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined with Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study. – Dr. Stephanie Tsai*

VA Committee

THURSDAY, OCTOBER 8 • 5:00 – 6:30 PM • WATER TOWER (CONCOURSE LEVEL, WEST TOWER)

Agenda

- A. *Introductions and Opening Comments***
Stephen Bartlett, RPh, MSPH, Chair
Brittany Rogers, MD, Vice-Chair
- B. *An Overview of the Dr. Charles D. Blanke Veterans' Access to Clinical Trials Initiative***
- C. *Presentation: Successful Storefront applications: the do's, don'ts and tips for the in between***
- D. *Q & A***
- E. *FDA New Guidance Presentation***
- F. *Open Call for Ideas on How to Better Partner with the VA National Oncology Program***
- G. *VA Accrual Update***
- H. *Wrap Up and Adjourn***

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Amrita Y. Krishnan, MD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Alex Herrera, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Brandon Richard Labadie, CCRP
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Yumena Kawasaki, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Saturday, October 10, 2026 11:30 a.m. - 1:30 p.m.
 Room: Comiskey (Concourse Level)

Agenda

Welcome & Introductions - Amrita Krishnan, MD, FACP

Keynote Speaker - Ola Landgren, MD, PhD

Active Trials Updates

1. S2213/BMT CTN 2025 - Patrick Hagen, MD
2. S1803/BMT CTN 1706 - Amrita Krishnan, MD, FACP
3. S2005 - Sikander Ailawadhi, MD
4. S2209 - Sikander Ailawadhi, MD

Update on Trials in Development

1. **S2508**, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and A. Cowan.
2. Phase III Non-inferiority RCT of Fixed Duration versus Continuous anti-CD38 in Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma - Hira Mian, MD & Jeries Kort, MD
3. Ramantamig Dara for NDMM - Murali Janakiram, MD & Sikander Ailawadhi, MD
4. A Randomized Phase II Study of Teclistamab + Iberdomide vs. Teclistamab Alone for Relapsed/Refractory Myeloma - Ricardo D. Parrondo, MD

Data use of closed trials/S0777 Manuscript - Sikander Ailawadhi, MD & Antje Hoering, PhD

TM Subcommittee update - J. Christine Ye., MD & Brian Walker, BSc, PhD

- Sample status S1803
- PO1 update

Other Cooperative Group Trials Updates

1. **A062102**, "Randomized Phase II Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24; Temporarily closed to accrual: 6/3/26.
2. **EEA173**, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. M. Butler. Activated: 4/30/19.
3. **EEA181**, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.
4. **EEA242**, "Randomized Phase Ib/II Study of Teclistamab + Pomalidomide (TP) vs. Carfilzomib + Pomalidomide + Dexamethasone (KPD) in Multiple Myeloma with Early Relapse"
5. **A062401**, "Quadruplet induction followed by teclistamab consolidation and doublet maintenance in patients with primary plasma cell leukemia: The QUANTUM Trial." Dr. Goldsmith

Barlogie-Salmon Myeloma Committee

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 3/1/26.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Li-pe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Li-pe. Activated: 11/9/12. Closed: 6/2/16; Completed: 4/17/26.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Santhorawala. Activated: 3/8/18; Closed: 9/30/19; Completed: 10/21/25.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

BMTCTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13; Completed: 11/15/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodapkar. Activated: 1/17/11. Closed: 7/14/17.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23; Completed: 1/31/25.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>A062102</i>	<i>EAA173</i>	<i>EAA181</i>
AdventHealth Parker	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	3	-	-	-	-
Boston Medical Center	5	-	-	3	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	2	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	1	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	23	2	-	-	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	6	-	-	-	-
Columbia University NCI Community Oncology Research Program	-	-	1	4	-	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	4	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	1	9	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	5	-	-	-	-
Henry Ford Hospital	2	1	-	-	-	4	2
Houston Methodist Hospital	13	-	-	2	-	-	-
Intermountain Medical Center	-	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	12	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-	-
Lahey Clinic	3	-	-	-	-	-	-
Loyola University Medical Center	26	-	-	1	-	3	4
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	1	-	-	-	2
Medical University of South Carolina NCORP Community Site	60	-	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	2	-	-	-	-
Moffitt Cancer Center	48	-	-	-	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>A062102</i>	<i>EAA173</i>	<i>EAA181</i>
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	5	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	-	3	9
Our Lady of the Lake Hospital	-	-	-	-	-	1	-
Pacific Cancer Research Consortium NCORP	18	-	7	1	-	-	-
Regents of the University of Michigan	16	-	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	4	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	15	-	5	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	35	-	-	1	-	-	-
Tulane University School of Medicine	-	-	-	-	-	2	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-	-
University of Arizona LAPS	12	-	-	-	-	-	5
University of Arkansas for Medical Sciences	-	-	8	-	-	-	5
University of California Davis Comprehensive Cancer Center	27	-	7	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	2
University of Kentucky/Markey Cancer Center	4	-	-	-	-	3	-
University of Nebraska Medical Center	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	5	-	-	-	-
University of Rochester LAPS	15	2	4	-	-	-	8
University of Texas MD Anderson Cancer Center LAPS	27	-	4	2	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	-	4	2
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	18	-	3	1	-	-	-
Wisconsin NCI Community Oncology Research Program	23	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	2	-	4	8
ALLIANCE	226	4	16	12	-	-	-
CCTG	21	-	-	-	-	-	-
ECOG-ACRIN	188	22	14	9	-	-	-
NRG	117	1	5	2	-	-	-
Total	1,338	34	136	46	1	44	48

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair: Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Allison Meisner, PhD
Shay Bellasea, MS
 Danika Lew, MA
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Andrew K. Godwin, PhD
 Shane Stecklein, MD, PhD
 Radiation Oncology: Eileen P. Connolly, MD, PhD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: TBD
 Pathology: David L. Rimm, MD, PhD
 Early Therapeutics: Stephanie L. Graff, MD

Designates

Adolescent & Young Adults: Erin Elizabeth Roesch, MD
 Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
Helen K. Chew, MD (Symptom Management)
 NCORP Representative: Philip E. Lammers, MD
 Veterans Affairs: Sarah V. Colonna, MD
 Data Coordinators: Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Larry G. Kaye
 Kevin Moralda, BS
 Oncology Research Professionals: Cameo Windham, BSN, RN
 Patient Advocates: Jamie LaScala
 Roberta A. Albany
 Pharmaceutical Science: Jorge G. Avila, PharmD
Dawud Nael Dawud Ellayan, PharmD
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Friday, October 9, 2026 4:15 p.m. - 6:15 p.m.
 Room: Regency A (Ballroom Level)

Agenda

4:15 - 4:20 pm Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

Mini Symposium: Optimizing Treatment for High-Risk Early-Stage TNBC

4:20 - 4:35 pm Residual disease post neoadjuvant therapy: Emerging treatment strategies - Shipra Gandhi, MD MS, Emory University

4:35 - 4:50 pm MRD monitoring in early-stage TNBC: Path to clinical utility - Bora Lim, MD, MDACC

4:50 - 5:05 pm Q&A

Committee Business and Updates

5:05 - 5:10 pm Publication Update – Allison Meisner, PhD

5:10 - 5:20 pm Patient Advocate Update – Roberta Albany & Jamie LaScala

5:20 - 5:30 pm Translational Medicine Subcommittee Update - Andrew K. Godwin, PhD & Shane Stecklein, MD, PhD

5:30 - 6:05 pm Review of Open and Upcoming CTSU Trials

6:05 - 6:10 pm Reports from Committee Liaisons
 NCORP - Philip Lammers
 Symptom Management & Survivorship - Lynn Henry
 Radiotherapy - Eileen P. Connolly
 Surgery - Joshua Mammen
 Cancer Care Delivery - Dawn Hershman
 Prevention, Screening and Surveillance– Banu Arun
 Theranostics Subcommittee: Shane Stecklein & Joanne Mortimer
 Early Therapeutics- Stephanie Graff

6:10 - 6:15 pm Closing Comments and Adjourn

NCI Approved Concepts

S2511, “Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy.” Approved: 7/17/25

Breast Committee

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Puztai. Activated: 10/30/23.

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 7/21/23.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21. Closed to accrual: 5/1/25.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18. Closed to accrual: 6/30/26.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21. Closed to accrual: 4/8/26.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16; Permanently closed: 6/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 9/4/13; Permanently closed: 5/1/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18. Permanently closed: 7/1/24.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20. Permanently closed: 4/7/25.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14; Permanently closed: 7/1/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 5/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15; Permanently closed: 4/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19; Permanently closed: 7/1/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17; Permanently closed: 12/2/22.

Breast Committee

Active Symptom Management and Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 9/15/17. Arms 1 and 2 permanently closed to accrual: 11/1/24.

Closed Symptom Management and Survivorship Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 2/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 3/1/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Study

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 7/16/18.

Closed Prevention, Screening, and Surveillance Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 9/1/20. Permanently closed: 6/14/24.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17; Permanently closed: 3/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Developing CTP Study

21CTP.BREAST01, "MONITOR (Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, Her2-negative Metastatic Breast Cancer)." Drs. Kalinsky, Bhave, and Ali.

Breast Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2007	S2206	S2212	A011801	A012103	A012301	A012303	EA1211	MA39
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	12	-	-	-	-	1
Baptist Memorial Health Care/Mid South NCORP Consort	-	6	19	-	-	-	-	2	-
Baylor College of Medicine/Duncan Comp Cancer Center	-	3	11	2	2	3	-	-	3
Boston Medical Center	-	-	1	6	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	1	-	-	-	-	6	-	-	2
Cancer Research Consortium of West Michigan NCORP	-	4	24	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	15	1	-	-	-	-	-
Cancer Research of Wisc and Northern Michigan Consor	-	1	18	-	-	1	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	2	6	20	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	7	4	1	1	1	-	-	-
City of Hope Comprehensive Cancer Center	-	3	25	-	-	-	-	-	1
Columbia University NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-
CommonSpirit Health Research Institute	-	2	13	-	-	-	-	-	2
Dartmouth College - Dartmouth Cancer Center LAPS	-	2	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	1	-	-	-	-	-	-	1
Essentia Health NCI Community Oncology Research Program	-	1	3	1	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	19	-	15	5	-	-	-
Georgia CaRes	-	-	1	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	2	13	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	3	14	-	1	-	-	1	-
Hartford Hospital	-	-	7	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	12	33	1	-	-	-	-	-
Henry Ford Hospital	-	3	12	2	9	5	-	-	3
Houston Methodist Hospital	-	-	-	2	3	-	-	-	3
Instituto Nacional De Cancerologia de Mexico	-	-	38	-	-	-	-	-	-
Intermountain Medical Center	-	-	12	-	-	7	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	-	-	41	-	-	-	-	-	-
Lahey Clinic	-	1	3	1	-	15	-	-	-
Loma Linda University Medical Center	-	-	6	-	1	1	-	-	-
Loyola University Medical Center	-	4	2	-	-	2	-	-	-
Medical University of South Carolina NCORP Community Site	-	4	-	-	1	-	-	-	10
Miami Cancer Institute	-	-	12	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	10	31	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	10	-	-	1	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	2	1	-	-	-	-	-	-
Mount Sinai Hospital	-	3	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	7	20	-	-	-	-	-	-
Northwell Health NCORP	1	3	10	-	-	-	-	-	-
Northwestern University LAPS	2	2	37	1	1	-	-	-	-

Breast Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2007	S2206	S2212	A011801	A012103	A012301	A012303	EA1211	MA39
Ohio State University Comprehensive Cancer Center LAPS	-	1	13	-	-	-	-	-	-
Oregon Health and Science University	-	6	3	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	16	34	-	-	-	-	-	5
Regents of the University of Michigan	-	6	15	2	3	-	-	-	15
Rhode Island Hospital	-	-	5	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	5	-	-	-
South Sound Care Foundation	-	7	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	1	13	55	1	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	12	3	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	1	3	-	4	-	-	-
The Hawaii NCORP	-	-	15	-	-	-	-	1	-
The NCI Comm Oncology Research Prgrm: The New Mexico NCORP	1	-	-	-	1	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	14	23	1	5	15	-	-	10
The West Clinic - Wolf River	-	-	35	-	-	-	-	-	-
Tufts Medical Center	-	-	1	-	1	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	4	-	2	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	3
UPMC Hillman Cancer Center LAPS	-	9	13	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	1	-	-	-	-	9
Universidad de la Republica - Facultad de Medicina	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep South Research Consort LAPS	2	-	6	-	-	-	-	-	-
University of Arizona LAPS	-	3	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	10	2	4	-	-	-	-
U of California Davis Comprehensive Cancer Center	-	-	-	-	3	13	-	-	-
University of Colorado Cancer Center LAPS	-	5	8	1	-	5	1	-	2
University of Kentucky/Markey Cancer Center	-	1	6	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	1	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	6	-	5	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	6	9	-	-	-	-	1	-
University of Rochester LAPS	-	-	1	-	-	4	-	-	-
University of Texas Health Science Center at San Antonio	4	9	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	2	3	-	-	-	-	3	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	2	2	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	2	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	6	18	2	-	-	-	4	4
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	-	3	10	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	5	39	3	-	-	-	-	-
ALLIANCE	7	55	260	-	-	-	-	-	-
ECOG-ACRIN	3	74	256	-	-	-	-	-	-
NRG	-	45	163	-	-	-	-	-	-
Total	28	386	1,495	55	57	99	4	9	76

Breast Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Arnot Ogden Medical Center/Falck Cancer Center	1	-	-
Banner MD Anderson Cancer Center	-	-	-
Baptist Memorial Health Care/Mid South NCORP Consort	-	1	-
Baylor College of Medicine/Duncan Comp Cancer Center	-	-	4
Boston Medical Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisc and Northern Michigan Consor	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University NCI Community Oncology Research Program	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	10
Georgia CaRes	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-
Hartford Hospital	-	-	-
Heartland Cancer Research NCORP	-	-	1
Henry Ford Hospital	-	-	2
Houston Methodist Hospital	2	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	6
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Clinic	-	-	-
Loma Linda University Medical Center	-	-	1
Loyola University Medical Center	-	-	1
Medical University of South Carolina NCORP Community Site	-	-	-
Miami Cancer Institute	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-
Mount Sinai Hospital	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
Northwell Health NCORP	2	-	-
Northwestern University LAPS	-	-	-

Breast Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Salem Hospital	-	-	-
South Sound Care Foundation	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	6	-	1
The Don and Sybil Harrington Cancer Center	-	-	5
The Hawaii NCORP	1	-	-
The NCI Comm Oncology Research Prgrm: The New Mexico NCORP	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	5	-	3
The West Clinic - Wolf River	-	-	2
Tufts Medical Center	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	3
U of Alabama at Birm/Deep South Research Consort LAPS	-	-	-
University of Arizona LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
U of California Davis Comprehensive Cancer Center	1	-	-
University of Colorado Cancer Center LAPS	4	-	1
University of Kentucky/Markey Cancer Center	-	-	-
University of Mississippi Medical Center	-	-	-
University of Nebraska Medical Center	1	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	-	1
University of Texas Health Science Center at San Antonio	10	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	1
Western States Cancer Research NCORP	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	34	1	44

Cancer Control & Prevention Committees

Leadership

Cancer Care Delivery Committee Co-Chairs: Veena Shankaran, MD
 Scott D. Ramsey, MD, PhD
 Palliative Care Committee Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention, Screening & Surveillance
 Committee Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO
 Symptom Management & Survivorship
 Committee Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD, MS (CCD, Prevention,
 Symptom Management)
 Virginia Sun, PhD, MSN, RN (Palliative)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Cathee Till, MS
 Matt Chansky, BS
 Sara Threlkel, BS
 Administrative Lead

Statistics & Data Management Center (SDMC): Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacroix, Jr. MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology Committee: Eileen P. Connolly, MD, PhD (CCD,
 Prevention)
 Kiri A. Cook, MD (Symptom Mgmt & Survivorship)
 Erin F. Gillespie, MD (Symptom Mgmt & Survivorship)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Mgmt & Survivorship)
 Dawn Hershman, MD (CCD)
 Banu Arun, MD (Prevention)
 Philip E. Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD

Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: TBD
 Melanoma Committee: Sancy Leachman, MD, PhD (Prevention)
 Recruitment and Retention Committee: Allison M. Caban-Holt, PhD
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Management)

Designates

Oncology Research Professionals: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Racheal Odom, MPH
 Melina D. Rodriguez, BS
 Shirley S. Sui, BS
 Samantha Wright, MS, CCRP
 Connie Szczepanek, RN, BSN
 Rachel C. Dooley, BSN, RN, OCN
 Melissa Maria Crane, BSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Data Coordinators: Kim Carvalho, BA
 Sam Dzingle, BA
 Manny Kharbanda, BA
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment and Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Kristin R. McJunkins (Prevention)
 Valerie Fraser (Palliative)
 Sr. Protocol Project Manager (CCD; Prevention): Patricia O'Kane
 Protocol Project Manager (Symptom Management): Elsie Duran
 Sr. Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care):
 Symptom Management: Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention): Sarah Cantu

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, October 8, 2026 11:30 a.m. - 1:30 p.m.

Room: Regency A (Ballroom Level)

Agenda

NCORP Grant Renewal Updates – Dawn Hershman, MD, MS, Scott Ramsey, MD, PhD, and Veena Shankaran, MD, MS

Patient Advocate Committee Updates – Barbara Segarra-Vazquez

Presentations

“Transforming Cancer Care; Innovation, Access, and Care Beyond The Walls,” Roxana Dronca, MD, Director, Mayo Clinic Comprehensive Cancer Center, Florida Cancer Programs; Director, Cancer Care Beyond Walls Program; Professor of Oncology, College of Medicine, and Science

“Pilot Trial of Debt Counseling for Patients with Cancer and Financial Hardship,” Chris Su, MD, MPH, Assistant Professor, Clinical Research Division, Fred Hutch; Affiliate Investigator, Hutchinson Institute for Cancer Outcomes Research (HICOR), Fred Hutch; Assistant Professor, Division of Hematology and Oncology, University of Washington

“Artificial Intelligence to Enhance Clinical Trial Enrollment: Opportunity vs Impact,” Kenneth Kehl, MD, MPH, Associate Director of Clinical Research, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School.

Developing Studies

Intervening on Oncofertility Care Delivery in Community Oncology Settings: A Parallel Cluster Randomized Controlled Trial. Sally Romero, PhD, MPH, University of California, San Diego; Claire Sathe, M.D., Columbia University Irving Medical Center

SXXXX, “Employment Outcomes & Cancer Care Delivery in Advanced Cancer Survivors,” Claire Sathe, M.D., Columbia University Irving Medical Center

“Artificial Intelligence-based Targeting Platform for Recruiting Cancer Clinical Trial Participants.” Nadine Housri, Co-Founder, MedNet; Associate Professor Adjunct, Yale School of Medicine

Active Studies

S2417CD, “A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance”. Drs. C. Veenstra and S. Hawley. Activated: 8/1/25.

S2424CD, “A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) To Improve Goals of Care Communication for People with Cancer”. Drs. R. Parikh, and M. Patel. Activated: 6/1/26.

Closed Studies

S1703, “Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer.” Dr. M. Accordini. Activated: 7/16/18. Step 1 (Screening) Closed: 8/15/26.

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. V. Shankaran. Activated: 7/26/21. Closed: 12/16/24.

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. J. Rueter, M. Trivedi, B. Symington, D. Hershman, S. Ramsey. Activated: 8/22/22. Closed: 11/22/24.

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1703	S2417CD	A191901	A231901CD	A232402CD	EAQ221CD	EAQ222CD
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	-	1	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	33	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	1	-	-	-
Cancer Research for the Ozarks NCORP	-	5	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	20	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	11	-	-	-	-	-	-
Columbia University NCI Community Oncology Research Program	28	2	-	-	-	-	-
Columbus NCI Community Oncology Research Program	4	-	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	2	-	-	1	-	-
Georgia NCI Community Oncology Research Program	4	3	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	8	-	-	-	-	-	-
Heartland Cancer Research NCORP	30	8	-	-	-	-	-
Henry Ford Hospital	-	-	4	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	2	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	8	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	-	-	-	4	-
Lahey Clinic	4	-	-	-	-	-	-
Loyola University Medical Center	5	-	8	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	28	8	-	-	-	-	-
Montana Cancer Consortium NCORP	5	3	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	1	-	-	-	-	-	-
Mount Sinai Hospital	9	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	6	11	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	2	-	1	-	-	-	-
Pacific Cancer Research Consortium NCORP	16	5	-	-	-	-	-
Riverside Methodist Hospital	2	-	-	-	-	-	-
Salem Hospital	5	-	-	-	-	-	-
South Sound Care Foundation	-	-	22	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	6	-	-	-	-	1	-
The Hawaii NCORP	12	1	-	-	-	-	34
The NCI Community Oncology Research Program: The New Mexico NCORP	18	-	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	13	-	-	-	-	-	6
Universidad de la Republica - Facultad de Medicina	3	-	-	-	-	-	-
University of Arizona LAPS	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	2	-	3	-	-	-	-
University of Rochester LAPS	4	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	2	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	16	-	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	-	-	2
Wisconsin NCI Community Oncology Research Program	9	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	56	-	-	-	-	-	-
ALLIANCE	22	20	-	-	-	-	-
ECOG-ACRIN	32	7	-	-	-	-	-
NRG	24	1	-	-	-	-	-
Total	461	94	42	2	1	5	42

Palliative Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Friday, October 9, 2026 8:00 a.m. - 10:00 a.m.
 Room: Regency A (Ballroom Level)

Agenda

1. Welcome and Introductions: Drs. Krouse and Bakitas

2. Committee Liaison Updates:

- Executive Officer: Virginia Sun, PhD
- Patient Advocates: Valerie Fraser and Lee Jones
- ORP Liaison: Shirley Sui

3. Updates on Studies:

Active Studies

S1501, "A Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity." Study Chairs: Justin Floyd, Monika Jacqueline Leja, Carol Fabian. Reopened 11/1/25

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Study Chairs: J. Sham, V. Pillarisetty, and R. Krouse. Activated: 2/14/25. Temporarily closed to accrual as of 3/16/26; reopening anticipated by the end of 2026

S2424CD, "Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer." Drs. Ravi B. Parikh, Manali Patel, and Christopher Manz.

Developing Studies

S2415 "Acupuncture to Decrease Symptom Burden in Patients with Metastatic Breast Cancer." Study Chair: Heather Greenlee

Secondary Studies

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Study Chairs: Robert Krouse, J. Deneve. Activated: 3/9/15. Permanently Closed: 5/15/20

Jyotsana Parajuli Project Updates

- Development and Initial Validation of a Palliative Care Readiness Tool for Older Adults with Cancer (NIH/NIA R15 AG081886-01A1)

- Participation of Older Adults from Underrepresented Backgrounds in SWOG Clinical Trials (SWOG ChEER Program)

4. Overview / Introduction of Working Groups

Early Access and Community-Based Delivery Models Working Group
 Meeting time: TBD

Lead

PCC Committee Co-Chair: Marie Bakitas

Members

Concepts in process

De-Escalation and Quality of Life Driven Endpoints

Meeting time: Every other Tuesday, beginning 9/1, 12:00-1:00 pm CT

Lead

PCC Committee Co-Chair: Marie Bakitas

Members

Concepts in process

GI Symptom Management and Supportive Care

Meeting time: Every other Friday, beginning 8/28, 10:00-11:00 am CT

Lead

PCC Committee Co-Chair: Robert Krouse

Members

Concepts in process

Discussion and next steps for concept development

5. Closing Remarks

Closed Studies

S1820, "A Randomized Phase II Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors (AIMS-RC)." Study Chair: Virginia Sun. Activated: 12/9/19. Closed to Accrual as of 4/12/22. Permanently Closed: 4/12/22

Palliative Care Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1501	S2408
Baptist Memorial Health Care/Mid South NCORP Consortium	7	-
CWRU Case Comprehensive Cancer Center LAPS	21	-
Cancer Research Consortium of West Michigan NCORP	-	8
Cancer Research for the Ozarks NCORP	11	-
City of Hope Comprehensive Cancer Center	53	-
Columbia University NCI Community Oncology Research Program	2	-
CommonSpirit Health Research Institute	1	-
Essentia Health NCI Community Oncology Research Program	-	1
Fred Hutchinson Cancer Research Center LAPS	4	2
Georgia NCI Community Oncology Research Program	15	-
Gulf South Clinical Trials Network (Gulf South NCORP)	2	-
Heartland Cancer Research NCORP	18	4
Henry Ford Hospital	7	-
Instituto Nacional de Enfermedades Neoplasicas	5	-
Kaiser Permanente NCI Community Oncology Research Program	1	-
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Clinic	7	-
Loyola University Medical Center	9	-
MU Health Care Goldschmidt Cancer Center	5	-
Medical University of South Carolina NCORP Community Site	1	-
Michigan Cancer Research Consortium NCORP	12	-
Moffitt Cancer Center	39	3
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	2	-
Northwestern University LAPS	-	6
Ohio State University Comprehensive Cancer Center LAPS	-	3
Oregon Health and Science University	1	-
Our Lady of the Lake Hospital	2	-
Regents of the University of Michigan	12	-
Southeast Clinical Oncology Research Consortium NCORP	2	-
The NCI Community Oncology Research Program: The New Mexico NCORP	12	-
The University of Kansas Cancer Centers- MCA Rural NCORP	7	-
UC San Diego Moores Cancer Center	-	5
USC Norris Comprehensive Cancer Center LAPS	4	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1
University of California Davis Comprehensive Cancer Center	2	-
University of Kentucky/Markey Cancer Center	-	8
University of Mississippi Medical Center	1	-
University of Nebraska Medical Center	-	2
Wayne State University/Karmanos Cancer Institute	6	-
Western States Cancer Research NCORP	2	-
Wisconsin NCI Community Oncology Research Program	-	5
ALLIANCE	40	5
ECOG-ACRIN	45	8
NRG	30	2
Total	394	63

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, October 8, 2026 2:00 p.m. - 4:00 p.m.
 Room: Regency A (Ballroom Level)

Agenda

1. Welcome and Opening Comments Banu Arun, MD &
 Jason Zell, DO

2. Presentation

"The CP-CTNet program and Portfolio of Clinical Trials" - Goli Samimi,
 PhD, MPH, Division of Cancer Prevention, National Cancer Institute

3. Triage and NCI Cancer Prevention Steering Committee Approved Studies

S2614, "A Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk Non-muscle Invasive Bladder Cancer (FIN-BC)." Drs. S. Psutka and P. Hensley.

4. Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

5. Concepts in Development

DCISionRT Biomarker for DCIS Concept, Dr. Eileen Connolly.

Prospective Trial of CRC Risk-Stratification and Screening in Young Adults Aged 35-44. Drs. Anoushka Dua, Li Hsu, Ulrike Peters, and Jason Zell.

QuitTech: A Technology-Enhanced Smoking Cessation Program for Cancer Patients and Survivors. Study Chair: Irene Tami-Maury, DMD, DrPH, MSc

6. Patient Advocate Update - Kristin McJunkins

7. Group Discussion

8. Other Group Prevention Studies with SWOG Accrual

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Banu Arun. Activated: 7/6/17. Closed: 12/20/24.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A212102	EA2185	EA8184	NRGCC005	NRGCC008
Audie L Murphy VA Hospital	69	-	4	4	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	3	-	-	6
CWRU Case Comprehensive Cancer Center LAPS	2	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	1	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	5	-	-	-	2
Henry Ford Hospital	7	-	-	-	-
Kansas City Veterans Affairs Medical Center	25	-	-	14	-
Loyola University Medical Center	8	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	40	-
Massachusetts Veterans Epidemiology Research and Information Center	32	8	-	97	-
Medical University of South Carolina NCORP Community Site	2	-	3	-	-
Northwell Health NCORP	-	-	-	-	1
Oregon Health and Science University	-	3	3	18	6
Our Lady of the Lake Hospital	4	-	-	-	-
The Don and Sybil Harrington Cancer Center	6	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	145	-	-	-	-
UC San Diego Moores Cancer Center	-	1	-	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-
University of California Davis Comprehensive Cancer Center	-	1	1	-	-
University of Colorado Cancer Center LAPS	5	-	-	21	-
University of Texas Health Science Center at San Antonio	20	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	14	-
Western States Cancer Research NCORP	1	-	-	-	-
Total	331	19	12	208	16

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, October 8, 2026 4:30 p.m. - 6:30 p.m.
 Room: Regency A (Ballroom Level)

Agenda

Overview Topics: Drs. Fisch and Henry

Patient Advocate Update: Lee Jones

BIQSFP Study Discussion:

"Pre-treatment Vitamin D Insufficiency to Predict Efficacy of Cryocompression for Prevention of Taxane-induced Peripheral Neuropathy" associated with "SWOG S2205 ICE-COMPRESS" - Dr. Daniel Hertz

Updates on Concepts in Development

"Impact of Intravenous Iron on Symptoms in Patients Receiving Adjuvant Systemic Anticancer Therapy for Colorectal Cancer." - Dr. Jamie Mills

Updates on Active Trials

Brainstorming Session - Building on the Working Group Ideas and Fostering Further Ideas for New Interventional SMS Study Concepts

Concepts in Development

SXXXX, "Vitamin D for Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Meghna Trivedi and Daniel Hertz.

SXXXX, "Lowering ANC Thresholds for Duffy Null Patients with Breast Cancer Receiving CDK 4/6 Inhibitor Therapy." Study Chair: Dr. Lauren E. Merz

SXXXX, "RECOG: Relugolix vs. GnRH agonist: Evaluation of COGNITIVE outcomes in prostate cancer." Study Chairs: Drs. Clara Hwang and Laura Graham

S2435, "App-Supported Sleep Coaching for Cancer Survivors and Their Bedroom Partners." Study Chair: Dr. Rina S. Fox.

SXXXX, "Impact of Intravenous Iron on Symptoms in Patients Receiving Adjuvant Systemic Anticancer Therapy for Colorectal Cancer" Study Chair: Dr. Jamie Mills

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective

Observational Study." Study Chairs: Drs. Krishna S. Gunturu and Dawn L. Hershman. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Melissa K. Accordino and Katheryn Pennington. Activated: 3/16/23.

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Study Chairs: Drs. Jill Hamilton-Reeves and Jeffrey M. Holzbeierlein. Activated: 02/21/19; Permanently closed: 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Study Chairs: Drs. Jessica Hwang, Anna S. Lok, Adam Gehring, and Jordan Feld. Activation: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Study Chairs: Drs. Meghna S. Trivedi, Dawn L. Hershman, and Thomas H. Brannagan. Activated: 03/01/19; Permanently closed: 11/15/21.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Study Chairs: Drs. N. Lynn Henry and Dawn L. Hershman. Activated: 1/17/23; Permanently closed: 1/15/25.

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Study Chairs: Drs. Reshma Jags, Pavani Chalasani, Jean Moran, and Corey Speers. Activated: 09/12/18; Permanently closed: 07/01/24.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Strmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Study Chairs: Drs. Melissa K. Accordino, Dawn Hershman, and Scott D. Ramsey. Activated: 7/16/18.

Symptom Management & Survivorship Committee

S1904, "Cluster Randomized Controlled Trial of Patient and Provider

Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Study Chairs: Drs. Katherine D. Crew, Rita Kukafka, Dawn L. Hershman, Parijatham Thomas, and Allison Caban-Holt. Activated: 9/1/20; Permanently closed: 6/14/24.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial

Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Study Chairs: Drs. Veena Shankaran, Ruth Carlos, Dawn L. Hershman, Shelby Langer, and Scott D. Ramsey. Activated: 7/26/21; Permanently closed: 12/16/24.

S2108CD, "A Cluster Randomized Trial Comparing an Educationally

Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Study Chairs: Drs. Jens Rueter, Meghna S. Trivedi, Banu E. Symington, Paul Tseng, and Dawn L. Hershman. Activated: 8/22/22; Permanently closed: 11/22/24.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST)

Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Study Chairs: Drs. Brian F. Chapin, Ana Aparicio, and Richard Valicent. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with

or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." SWOG Study Chair: Drs. Parminder Singh, Seth P. Lerner, and Sameer Jhavar. Activated: 04/19/18; Permanently closed: 04/01/24.

GI

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and

Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Study Chairs: Drs. Jason A. Zell, Lance, and Powel H. Brown. Activated: 3/1/13; Permanently closed: 6/30/23.

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax

and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Study Chairs: Drs. Deborah Stephens, Brian Hill, and Maziar Shadman. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation

Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Study Chairs: Drs. Megan E. Daly, Charles B. Simone, II, Karen Kelly, and Jeffrey D. Bradley. Activated: 3/25/20.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and

Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Study Chairs: Drs. Chad Rusthoven, Paul Brown, Jeffrey S. Wefel, Abhijit Patel, and N. Lynn Henry. Activated: 1/10/20; Permanently closed: 12/15/25.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or

Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age $\geq$ 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Study Chairs: Drs. Alex F. Herrera and Jonathan Friedberg. Activated: 7/19/19; Permanently closed: 12/1/22.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without

Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Study Chairs: Drs. Elizabeth Brem and Sonali Smith. Activated: 3/19/21; Temporarily closed: 4/1/25.

Myeloma

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) +

Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Study chairs: Drs. Amrita Krishnan, Saurabh Chhabra, and Natalie S. Callander. Activated: 6/27/19; Step 1 Closed to accrual: 1/15/25.

NETN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy

(COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Caio Max Sao Pedro Rocha Lima and Michael Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21; Permanently closed: 9/2/25.

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202
Audie L Murphy VA Hospital	-	26	-	-	-	-	-
Baptist Memorial Health Care/Mid South NCORP Consortium	-	8	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	190	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	21	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
Columbia University NCI Community Oncology Research Program	25	58	44	-	1	-	-
Columbus NCI Community Oncology Research Program	-	37	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Georgia CaRes	-	40	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	78	-	3	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	25	287	-	-	-	-	-
Henry Ford Hospital	-	29	5	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	24	-	-	-	-	-	-
Intermountain Medical Center	-	3	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	89	-	-	-	-	-
Lahey Clinic	12	63	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	63	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	29	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	1	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	8	-	-	-	-	39
Nevada Cancer Research Foundation NCORP	-	-	-	-	3	-	4
Northwestern University LAPS	7	-	-	-	-	-	-
Oregon Health and Science University	-	12	-	-	-	2	-
Our Lady of the Lake Hospital	-	25	-	-	-	-	-

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202
Pacific Cancer Research Consortium NCORP	11	6	-	-	-	-	-
Regents of the University of Michigan	31	-	-	-	-	-	-
Rhode Island Hospital	-	-	25	-	-	-	-
STCC at DHR Health Institute for Research and Development	18	55	42	8	-	-	-
Salem Hospital	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	204	102	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	8	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	10	4	-	-	1	-	-
The Hawaii NCORP	9	11	53	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	21	-	30	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	18	94	22	1	-	3	-
Tufts Medical Center	-	-	-	-	-	-	4
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	6	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	5	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	4	22	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	8	-	-	-	-
University of Arizona LAPS	-	5	-	-	-	-	-
University of Arkansas for Medical Sciences	6	25	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	7	13	-	-	-	-	-
University of Colorado Cancer Center LAPS	3	38	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	17	53	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	3	-	6	2	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	29	-	-	-	-
Western States Cancer Research NCORP	-	1	4	-	-	-	-
Wisconsin NCI Community Oncology Research Program	8	37	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	-	-	-	-
ALLIANCE	42	385	94	-	-	-	-
ECOG-ACRIN	37	140	15	-	-	-	-
NRG	87	311	153	-	-	-	-
Total	565	2,543	633	18	7	13	47

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EAQ211	NRGCC010	NRGCC011	NRGCC014	NRGCC015
Audie L Murphy VA Hospital	-	-	-	-	-
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	3	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	3	-	-
Columbia University NCI Community Oncology Research Program	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	1	-	-
Essentia Health NCI Community Oncology Research Program	1	-	-	-	-
Georgia CaRes	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	15	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	1
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-
Lahey Clinic	-	-	4	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-
Mount Sinai Hospital	-	-	2	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EAQ211	NRGCC010	NRGCC011	NRGCC014	NRGCC015
Pacific Cancer Research Consortium NCORP	-	-	-	-	-
Regents of the University of Michigan	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-
Salem Hospital	-	-	14	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-
Stanford Cancer Institute Palo Alto	4	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	16	-
The Don and Sybil Harrington Cancer Center	-	-	3	-	4
The Hawaii NCORP	-	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	2	-	12	1	-
Tufts Medical Center	-	-	-	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-
University of Arizona LAPS	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	-	-	2	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-
University of Mississippi Medical Center	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	2	-	-	-
University of Rochester LAPS	12	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	5	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	19	17	48	22	10

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Megan Othus, PhD
 Alejandro Hernandez, MS
 Anna B. Moseley, MS
 Sara Threlkel, BS

Liaisons

Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgil, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Designates

Data Coordinator: Christine Magner
 Veterans Affairs: Jimmy Ruiz, MD
 Oncology Research Professionals: Adam Platt, BS
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Bill Minh Thach, MBA
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 8, 2026 11:00 a.m. - 1:30 p.m.

Room: Registry C (Ballroom Level)

Agenda

11:00 - 11:10 am Welcome and Introduction - Razelle Kurzrock, MD

11:10 - 11:35 am SN2426, "A Randomized Phase II Study of Amivantamab Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma

21CTP.HN01, "CAPT-HN-A Phase II Study of Combined Amivantamab, Carboplatin, and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer - Paul Swiecki, MD

11:35 - 12:00 pm MRD Concept - Young Kwang Chae, MD, MPH, MBA

12:00 - 12:25 pm Updates from Sarcoma Working Group & S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard FRACTIONATION (RT-25) for Stage II-IIIb, Extremity, Resectable Soft Tissue Sarcoma." - Lara Davis, MD & Jeremy Harris, MD, MPhil

12:25 - 12:50 pm Overview of Additional Analyses of DART - Megan Othus, PhD

12:50 - 1:15 pm MD Anderson Cancer Center, NCI CIMAC (Cancer Immune Monitoring and Analysis Centers) Updates on S1609: Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors) - Cara Haymaker, PhD

1:15 - 1:30 pm Wrap Up - Razelle Kurzrock, MD

Active Studies

S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard FRACTIONATION (RT-25) for stage II-IIIb, extremity, resectable Soft Tissue Sarcoma". Drs. Harris, Davis. Activated: 7/6/2026.

SN2426, "A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma." Dr. Swiecicki, Geiger (NRG Study Chair) Activated: 1/28/2026.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/03/2022.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

Early Therapeutics & Rare Cancers Committee

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 12/17/2024.

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thorascopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma" SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 09/06/2023

CTSU/ HN.11 (CCTG-HN11), "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG" Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Studies in Development

S2702, "A Randomized Phase II/III Trial of Zanzalintinib Plus Temozolomide and Gemcitabine Plus ATX-101 Versus Gemcitabine and Docetaxel in Patients with Unresectable or Metastatic Leiomyosarcoma". Dr. Mark Agulnik

"A Randomized Phase II Trial to Evaluate Frontline Combination Immunotherapy of Cemiplimab, Fianlimab, Carboplatin, and Paclitaxel versus Investigator Choice Anti-PD-1/ PDL1 based Chemo-ICI for Metastatic Large Cell Neuroendocrine Carcinoma of the Lung: FIRST-LUNG". Dr. Naqash

Closed Studies

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23. Closed: 06/02/2025.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Closed: 05/23/2025

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia.

Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 05/10/2024

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCICOVID, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/2022

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus OV1821BN1 Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

Early Therapeutics & Rare Cancers Committee

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

NRG-HN1854, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

NRG-UC1805, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

ComboMATCH Studies in Development

EAY191-S9, "Phase II Study of Inavolisib in Combination with Ribociclib in PIK3CA Aberrated Head & Neck or NSMP Endometrioid Endometrial Cancers." Drs. B. Nelson and J. Rodon.

ComboMATCH Closed Studies

EAY191-S3, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Drs. R. Basho and H. Mahdi. Activated: 3/6/23. Closed: 8/3/26.

CTP Active Studies

21CTP.HN01, CAPT-HN: "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner. Activation: 09/15/2025

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2012	SN2426	EAY191-S3	21CTP HN01	A071401	AGCT1531	AGCT1532
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	1	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	7	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	2	-	-	-	-
CommonSpirit Health Research Institute	1	-	-	-	1	-	-
Duke University - Duke Cancer Institute LAPS	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	18	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	3	1	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-
Henry Ford Hospital	2	-	-	-	1	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	5	-	1	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	1	-
Northwestern University LAPS	5	-	-	-	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	12	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	4	-	1	-	-	-	-
Regents of the University of Michigan	2	4	-	5	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	1	-
The Hawaii NCORP	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	1	-	-
UC San Diego Moores Cancer Center	-	-	-	-	2	3	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	5
University of Colorado Cancer Center LAPS	-	-	-	-	1	-	-
University of Rochester LAPS	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	3	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	4	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	10	1	-	-	2	-	-
ALLIANCE	28	-	6	-	-	-	-
ECOG-ACRIN	16	-	9	-	-	-	-
NRG	13	1	10	-	-	-	-
Total	163	7	33	5	9	5	5

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EA7211	EAY191	EAY191A3	EAY191A6
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-
Cedars-Sinai Medical Center	-	5	-	-
CommonSpirit Health Research Institute	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	1	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Mount Sinai Hospital	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Regents of the University of Michigan	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-
The Hawaii NCORP	-	1	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	1
UC San Diego Moores Cancer Center	-	1	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-
University of Rochester LAPS	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	10	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	2	22	2	2

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Hagen F. Kennecke, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Sara Threlkel, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsachacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David P. Horowitz, MD (Radiation Oncology)
 AYA Committee Liason: Christopher Cann, MD
 Veterans Affairs: TBD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals: Adriana Gamboa Guzman, BA
 Samantha Elliott, CCRP
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): Lisa Craine
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Sr. Protocol Project Manager: Andrea Garcia, BA
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, October 9, 2026 4:30 p.m. - 6:30 p.m.
 Room: Crystal C (Lobby Level)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Marielle McLeod,
Colmar Figueroa-Moseley
4. Featured Presentation Topic & Speaker Forthcoming
5. SWOG Led Active Trials
 - a. S2104 Heloisa Soares/S. Ahmad
 - b. S2012 David Zhen/E. Gabriela Chiorean
 - c. S2303 Anwaar Saeed/Paul Oberstein
 - d. S2408 Jonathan Sham/Venu Pillarisetty
 - e. S2433 Rachael Safyan/E. Gabriela Chiorean
6. Upcoming SWOG Trial Activations
 - a. S2605 Sameer Patel/Sean Dineen
7. Gastroesophageal
 - a. Major recent clinical results Syma Iqbal, Zev Wainberg
 - b. NCTN trials update
 - c. Future SWOG plans
8. Pancreatic Davendra Sohal, Andrew Lowy
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans

Gastrointestinal Committee

9. Colon

Marwan Fakih, Philip Gold,
Sepideh Gholami

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

10. Anal and Rectal

Hagen Kennecke, Lisa Kachnic

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

11. Hepatobiliary

Anthony El-Khoueiry
Rachna Shroff

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

12. Neuroendocrine

Arvind Dasari, Aman Chauhan

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

13. Discussion/Other Business

14. Adjourn

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)" Study Chairs: A. Saeed and P. Oberstein. Activated: 5/6/2024.

A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma" SWOG Champion: P. Oberstein. Activated: 1/17/2019.

EA2174, "A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma" SWOG Champion: S. Iqbal. Activated: 1/17/2019. Temporarily closed to accrual as of 12/29/2022.

EA2212, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer" SWOG Champion: Emerson Chen. Temporarily closed to accrual as of 12/04/2024.

Closed Studies

A021302, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study" SWOG Champion: S. Iqbal. Activated by SWOG: 4/1/2016. Closed to accrual on 06/01/2017.

EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2-Negative Esophageal and Gastric Adenocarcinoma (EGA)" SWOG Champion: D. Horowitz. Activated: 2/6/2020. Closed to accrual as of 05/23/2025.

Pancreatic

Active Studies

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula" Study Chairs: J. Sham, V. Pillarisetty, and R. Krouse. Activated: 2/14/2025. Temporarily closed to accrual as of 03/16/2026; reopening anticipated by the end of 2026.

S2433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma" Study Chairs: R. Safyan, E. Chiorean, and H. Singh. Activated: 12/26/2025.

EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation" SWOG Champions: E. Chiorean and P. Philip. Activated: 4/29/2021.

Closed Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or 2 Mutations" Study Chairs: V. Chung and M. Pishvaian. Activated: 12/04/2020. Closed to accrual as of 10/23/2025.

S1505, "Preoperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Randomized Phase II Study" Study Chair: D. Sohal. Activated: 10/12/2015. Closed: 4/20/2018.

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT)" SWOG Champion: D. Zhen. Activated: 6/18/2020. Closed to accrual as of 10/17/2023.

Gastrointestinal Committee

RTOG-0848, “Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study” SWOG Champion: P. Philip. Activated by SWOG: 12/15/2009. Closed to accrual and treatment as of 01/18/2019.

A021501, “Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas” SWOG Champion: S. Ahmad. Activated by SWOG: 12/15/2016. Closed to accrual as of 05/06/2019.

A022106, “A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)” SWOG Champion: G. Botta. Activated: 12/1/2023. Closed to accrual as of 12/24/2025.

A021806, “A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer” SWOG Champion: S. Behrman. Activated: 7/1/2020. Closed to accrual as of 01/05/2026.

Neuroendocrine

Active Studies

S2104, “A Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors” Study Chairs: H. Soares and S. Ahmad. Activated: 10/14/2021.

S2012, “Randomized Phase II/III Trial of First-Line Platinum/Etoposide with or without Atezolizumab in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)” Study Chairs: D. Zhen, E. Chiorean, E. Burgess, E. Swisher, and L. Byers. Activated: 12/02/2021.

CCTG-NE1, “NET RETREAT: A Phase II Study of 177Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours” Activated by SWOG: 6/17/2022.

Closed Studies

A021602, “Randomized Double-Blinded Phase III Study of Cabozantinib versus Placebo in Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)” SWOG Champion: J. Strosberg. Activated: 7/18/2018. Closed to accrual as of 09/08/2023.

EA2142, “Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas” SWOG Champion: H. Soares. Activated: 11/6/2015. Closed to accrual and treatment as of 04/01/2021.

EA2161, “A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)” Activated: 2/1/2017. Closed to accrual and treatment as of 12/27/2019.

A021804, “A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma” SWOG Champion: C. Lopez. Activated: 11/2/2020. Closed to accrual as of 06/02/2025.

Hepatobiliary

Closed Studies

S1815, “A Randomized Phase III Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin Alone in Advanced Biliary Cancers” Study Chairs: R. Shroff and A. Scott. Activated: 12/3/2018. Closed: 02/15/2021.

NRG-GI003, “A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma” SWOG Champion: A. El-Khoueiry. Activated: 6/21/2017. Closed to accrual as of 01/14/2026.

EA2187, “A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma” SWOG Champion: Stacy Stein. Activated: 1/31/2020. Closed to accrual as of 03/22/2023.

RTOG-1112, “Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma” SWOG Champion: T. Mitin.

EA2197, “Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial” SWOG Champion: F. Rocha. Activated: 12/22/2020. Closed to accrual as of 04/18/2025.

Colorectal

Active Studies

A022101, “A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)” SWOG Champion: S. Gholami. Activated: 1/10/2023.

Gastrointestinal Committee

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial" SWOG Champion: Skye C. Mayo. Activated: 10/19/2023.

NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)" SWOG GI Committee Co-Chairs: P. Philip and C. Eng. Activated: 03/10/2022.

In Development

S2605, "A Phase III Trial of Preoperative Chemotherapy vs. Surgery First (CRS-HIPEC) for High-Grade Appendiceal Cancer" Study Chairs: S. Patel, S. Dineen, and K. Raghav. In development; target activation: 12/15/2026.

Closed Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma" Study Chair: M. Overman. Activated: 12/16/2019. Closed: 7/15/2026.

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAF V600E Metastatic Colorectal Cancer" Study Chair: V. Morris. Activated: 06/06/2022. Closed to accrual: 10/1/2024.

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab Compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer with HER2 Amplification" Study Chair: K. Raghav. Activated: 10/19/2017. Step 3 permanently closed: 11/30/2023.

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers (PACES)" Study Chair: J. Zell. Activated: 3/1/2013. Permanently closed: 6/30/2023.

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC)" SWOG Champion: G. Lieu. Activated: 9/12/2017. Closed to accrual as of 01/17/2023.

A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)" SWOG Champion: S. Cohen. Activated: 9/30/2019. Closed to accrual as of 12/15/2022.

E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without Ramucirumab in Advanced KRAS Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy"

SWOG Champion: H. Hochster. Activated: 10/18/2010. Closed to accrual as of 7/07/2017.

NRG-GI004 / S1610, "Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT): A Randomized Phase III Study of mFOLFOX6/Bevacizumab with or without Atezolizumab or Atezolizumab Monotherapy" SWOG Champion: M. Overman. Activated: 11/7/2017. Closed to accrual as of 09/02/2025.

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)" SWOG Champion: A. Scott. Activated: 12/16/2019. Closed to accrual as of 02/12/2024.

Rectal/Anal

Active Studies

CCTG-CO32, "The NEO-RT Trial: A Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy for Early Rectal Cancer" SWOG Champion: S. Cohen. Activated by SWOG: 7/10/2023.

Closed Studies:

N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined-Modality Chemoradiation versus Preoperative Combined-Modality Chemoradiation for Locally Advanced Rectal Cancer" SWOG Champion: C. Eng. Activated: 4/15/2012.

EA2133 (InterAACT), "An International Multicentre Open-Label Randomised Phase II Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Advanced Anal Cancer" SWOG Champion: V. Morris. Activated: 2/15/2016.

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer" SWOG Champion: L. Kachnic. Activated: 10/12/2016. Closed to accrual as of 05/14/2019.

EA2165, "A Randomized Phase II Study of Nivolumab After Combined-Modality Therapy in High-Risk Anal Cancer" SWOG Champion: V. Morris. Activated: 4/13/2018. Closed to accrual as of 04/04/2022.

A022104, "The JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Locally Advanced Rectal Cancer" SWOG Champion: A. Dasari. Activated: 11/9/2022. Closed to accrual as of 07/21/2025.

Gastrointestinal Committee

EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer" SWOG Champion: V. Morris. Activated: 10/15/2020. Closed to accrual as of 09/23/2024.

EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma" SWOG Champion: R. Hsieh. Activated: 5/13/2021. Closed to accrual as of 01/14/2025.

EA2182, "A Randomized Phase II Study of De-Intensified Chemoradiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)" SWOG Champion: J. Murphy. Activated: 11/12/2019. Closed to accrual as of 10/30/2024.

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1922	S2001	S2104	S2303	S2433	A021806	A022001	A022101	A022102
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	2	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-	-	3	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	1	1	4	1	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	4	5	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	3	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	2
Fred Hutchinson Cancer Research Center LAPS	-	-	3	-	-	2	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-	-	-	-	1	-
Heartland Cancer Research NCORP	1	1	-	-	-	-	-	-	-
Henry Ford Hospital	-	4	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	4	-	1	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	5	-	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	1	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	1	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	1	2	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	4	4	-	5	-	-	-
Pacific Cancer Research Consortium NCORP	1	2	6	1	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1922	S2001	S2104	S2303	S2433	A021806	A022001	A022101	A022102
Regents of the University of Michigan	4	3	4	-	-	4	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-	-	-
The Hawaii NCORP	-	-	-	2	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	1	-	-	-	-	8
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	-	-	-	-	-	7
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	6	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	3	-	-	-	-	2
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	1
University of Arizona LAPS	-	-	11	-	-	1	-	-	-
University of Arkansas for Medical Sciences	-	-	-	2	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	5	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	3	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	1	-	-	3	-	12	-	-	9
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-
University of Texas MD Anderson Cancer Center LAPS	17	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	7	2	-	-	1	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	5	-	1	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	1	-	-	-	-	-	-	7
Wisconsin NCI Community Oncology Research Program	-	-	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	4	-	2	1	-	-
ALLIANCE	12	8	13	32	1	-	-	-	-
ECOG-ACRIN	3	16	13	12	-	-	-	-	-
NRG	3	9	10	7	-	-	-	-	-
Total	47	73	103	106	1	37	2	1	41

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2192	EA2197	EA2222	EA2234	NRGGI004
Banner MD Anderson Cancer Center	-	-	-	-	-	-	1	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	13	-	-	-	-	-	-	-	-
Boston Medical Center	6	-	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	9	3	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	5	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1
Intermountain Medical Center	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	1	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-	-	-
Oregon Health and Science University	-	3	-	-	4	6	2	-	-
Pacific Cancer Research Consortium NCORP	-	2	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2192	EA2197	EA2222	EA2234	NRGG1004
Regents of the University of Michigan	1	-	-	-	-	-	1	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	2	-	-	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	17	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	5	3	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	1	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	-
University of Arizona LAPS	-	-	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	4	-	-	-	-	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	4	1	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	23	-	-	-	-	-	-	-	1
University of Texas Health Science Center at San Antonio	8	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	13
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	8	1	-	-	-	1	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	110	14	7	6	6	9	8	1	15

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGI006	NRGGI008
Banner MD Anderson Cancer Center	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	2
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	1
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	1
Essentia Health NCI Community Oncology Research Program	-	-
Fred Hutchinson Cancer Research Center LAPS	-	14
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	1
Houston Methodist Hospital	-	-
Intermountain Medical Center	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	-
Loma Linda University Medical Center	-	1
Massachusetts Vets Epidemiology Research & Information Center	-	3
Medical University of South Carolina NCORP Community Site	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-
Mount Sinai Hospital	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Northwell Health NCORP	-	1
Northwestern University LAPS	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGG1006	NRGG1008
Regents of the University of Michigan	-	-
STCC at DHR Health Institute for Research and Development	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-
Sutter Cancer Research Consortium	-	2
The Don and Sybil Harrington Cancer Center	-	-
The Hawaii NCORP	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-
The West Clinic - Wolf River	-	5
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-
University of Arizona LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of California Davis Comprehensive Cancer Center	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-
University of Colorado Cancer Center LAPS	-	11
University of Kentucky/Markey Cancer Center	-	-
University of Nebraska Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	1	1
University of Rochester LAPS	-	19
University of Texas Health Science Center at San Antonio	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	3
Virginia Mason Medical Center	-	-
Wayne State University/Karmanos Cancer Institute	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	1	69

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Gabby Lopez, MS
 Sara Threlkel, BS

Scientific Leadership

Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)
 Translational Medicine: Joshua J. Meeks, MD, PhD (GU Chair)
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 David A. Braun, MD, PhD (Renal)
 Special Advisor: David J. McConkey, PhD
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Accrual Champion: Jessica D. McDermott, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Aihua Edward Yen, MD
 International Liaison: Sumanta "Monty" Pal, MD
 Data Coordinators: Laura Wells, BA
 Tonya Johnson, BS
 Michele Counts, BS
 Oncology Research Professionals: Abigail L. Cornette, MS
 Gary Lee Duvall, RN

Patient Advocates: Darrell Nakagawa (Bladder)
 Joël R. Pointon, MPH (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Catherine Chen, PharmD
 Sr. Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Sarah Cantu

Time/Location

Saturday, October 10, 2026 9:15 a.m. - 11:15 a.m.

Room: Regency A (Ballroom Level)

Agenda

9:15 - 9:30 am: Chair's Welcome and Opening Remarks - Seth Lerner
 9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka
 9:55 - 11:15 am: Review of open approved trials - all organ site chairs
 Bladder – Sia Daneshmand and Tom Flaig
 Prostate – Tanya Dorff and Daniel Lin
 Renal – Brian Shuch and Ulka Vaishampayan

Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

Active Studies

S1931 (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

S1937 (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S2427, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer

Genitourinary Committee

(BRIGHT)." Dr. L. Ballas. Activated 9/4/2025. Revision #1 released 1/15/2026.

Concepts in Development

S2611, "A Randomized Comparison of Intravesical TherapieS (ARCIS): A randomized phase III study of intravesical gemcitabine and docetaxel (GEM-DOCE) versus intravesical cretostimogene grenadenorepvec and gemcitabine (CRETO-GEM) for the treatment of bacille Calmette-Guérin (BCG)-unresponsive and BCG-exposed non-muscle invasive bladder cancer (NMIBC)." Dr. M. Tyson. GU Steering Committee approved 6/15/2026. Protocol is currently in development.

Active Studies

CTSU/A031701, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20. Closed to accrual: 7/23/2025.

CTSU/EA8185, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20. Closed to accrual: 10/2/2023.

CTSU/EA8192, "A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy" Drs. S. Psutka and A. Tripathi. Activated: 5/6/21. Arm C Closed to Accrual as of 04/25/2025.

Closed Studies

S1011, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19. FDAAA/IRB Completed.

S2011, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23. Administratively Complete.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 released 8/15/2025. Closed to accrual and treatment: 4/1/2024.

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25. Study closed to accrual 3/13/2026.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23.

Concepts in Development

S2613, "Assessing the Need for Pelvic Lymphadenectomy at the Time of Prostatectomy for Prostate Cancer with PSMA-PET Based Evaluation: a Multicenter, Randomized Phase III Clinical Trial." Drs. Udit Singhal and Todd Morgan. GU Steering Committee approved 7/17/2026. Protocol is currently in development.

Active Studies

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24. Revision #1 released 1/15/2026.

Genitourinary Committee

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15. Closed to Accrual 10/26/2022.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18. Closed to Accrual 2/28/2025.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21. Closed to Accrual 6/26/2025.

CTSU/EA8191, "Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)." Dr. N. Vapiwala. Activated: 10/8/202. Arms A & B Closed to Accrual 1/31/2025.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16. Closed to Accrual 9/6/2022.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21. Closed to Accrual 8/18/2025.

CTSU/NRGGU010, "Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)." Drs. N Desai and A. Berlin. Activated: 11/3/2021. Groups 3 and 4 Closed to Accrual 11/22/2024.

Drs. N Desai and A. Berlin. Activated: 11/3/2021. Groups 3 and 4 Closed to Accrual 11/22/2024.

CTSU/NRGGU011, "A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHERapy with or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)." Dr. B. Koontz.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25. FDAAA/IRB Completed.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22. Closed to Accrual and Treatment 6/8/2022.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RT0G-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

Genitourinary Committee

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21. Stratum 2 Temporarily Closed to Accrual as of 12/17/2024. AYA-HEARS Ototoxicity PRO Study Temporarily Closed to Accrual as of 02/12/2021.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20. Revision #10 released on 2/2/2026.

Active Studies

CTSU/AREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22. Closed to Accrual 03/24/2023.

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21. Closed to Accrual 5/15/2024.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19. Closed to Accrual 12/19/2025.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20. Closed to Accrual 11/29/2022.

S2419, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. Activated 4/22/2026.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently Closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)." Drs. B. Maughan and S. Pal. Activated 9/19/22. Temporarily closed to accrual 1/17/2026. Permanently Closed: 3/1/2026.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Translational Medicine

Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Roger Li

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. David Braun

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51. Closed to Accrual 3/15/2023.

Genitourinary Committee

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Open Cohorts: A, C, D, J, H, L. Temporarily Closed Cohorts: B, E, F, G, I K.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; Closed to Accrual 12/23/2022.

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1802	S1931	S1937	S2200	S2210	S2312	S2419	S2427	A021804	A031701
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Comprehensive Cancer Cntr	7	-	1	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	11
Cancer Research Consortium of West Michigan NCORP	2	1	1	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	-	-	1	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	3	-	1	-	-	1	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	1	1	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	11	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	4	-	-	-	-	-	1	-	-
City of Hope Comprehensive Cancer Center	5	3	-	7	1	1	-	1	-	-
CommonSpirit Health Research Institute	3	-	5	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	2	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	28	-	-	-	3	-	-	-	-	-
Georgia CaRes	1	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	7	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	85	3	2	1	1	-	-	-	-	-
Hartford Hospital	-	-	-	-	-	1	-	-	-	1
Heartland Cancer Research NCORP	11	1	-	3	-	1	-	-	-	2
Henry Ford Hospital	33	1	4	-	-	-	-	-	-	-
Houston Methodist Hospital	-	2	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	10	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	41	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	2	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	22	2	-	-	-	-	-	-	-	-
Lahey Clinic	-	-	-	-	-	-	2	-	-	-
Loyola University Medical Center	9	1	2	-	-	-	-	-	-	-
Malcom Randall Vets Administration Medical Center	-	-	-	-	-	-	-	-	-	-
Mass Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	8	-	4	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	17	-	4	2	-	4	-	-	-	1
Moffitt Cancer Center	-	-	-	-	-	-	-	2	-	-
Montana Cancer Consortium NCORP	5	1	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	2	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	12	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1802</i>	<i>S1931</i>	<i>S1937</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>S2419</i>	<i>S2427</i>	<i>A021804</i>	<i>A031701</i>
Northwestern University LAPS	-	1	1	1	-	3	-	1	-	-
Ohio St University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	3	3	1	1	1	-	-	1	-
Regents of the University of Michigan	2	27	4	-	-	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	9	-	-	-	-	3	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	2	1	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	7	-	4	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	5	-	-	-	-	-	-	-
Tulane University School of Medicine	-	9	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	11	1	4	-	-	1	-	-	-	-
UC San Diego Moores Cancer Center	8	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	4	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	2	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	10	2	17	-	-	-	-	1	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	7	-	-	-	-	-	3	-	-
University of Arizona LAPS	7	3	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	1	-	2	-	-	-	-
U of California Davis Comprehensive Cancer Center	18	5	6	-	-	-	-	-	-	11
University of Cincinnati Cancer Center-UC Medical Cntr	8	3	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	10	-	10	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	2	-	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	1	1	-	-	-	-	-	-
University of Nebraska Medical Center	10	-	-	-	-	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	47	6	8	3	-	5	-	1	-	-
University of Rochester LAPS	26	4	-	-	-	-	-	-	-	2
University of Texas Health Science Center at San Antonio	2	7	-	-	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	92	-	-	-	-	18	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	20	2	4	4	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	3	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	16	1	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	4	-	-	2	-	-	-	-
ALLIANCE	125	9	7	2	-	12	-	5	-	-
ECOG-ACRIN	111	17	22	6	-	5	-	5	-	-
NRG	129	16	3	4	-	-	-	2	-	-
Total	1,039	154	132	36	6	64	2	22	1	28

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A031702	A031801	A031803	A032102	A032103	A032201	A032302	A032303	A032304	CCTG-PR24
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	2	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	1	-	-
Baylor College of Medicine/Comprehensive Cancer Cntr	-	-	6	-	5	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-	-
Georgia CaRes	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	1	16	-	-	-	-	-	-	-
Hartford Hospital	-	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	2	-	-	-	2	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	-	-	-	-	1	-	-	-	-	3
Lahey Clinic	7	-	-	-	-	1	-	-	-	-
Loyola University Medical Center	1	-	-	-	-	-	-	-	-	-
Malcom Randall Vets Administration Medical Center	-	-	-	-	1	-	-	-	-	-
Mass Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A031702	A031801	A031803	A032102	A032103	A032201	A032302	A032303	A032304	CCTG-PR24
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	6	-	-	-	7	6	-	-	-	-
Regents of the University of Michigan	-	-	-	-	4	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	1	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-	-	-	-	3	-	-	1	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	1	1	12	-	-	-	-	2	-	-
University of Arizona LAPS	-	-	-	-	3	3	3	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	-	7	5	3	3	1	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-	-	-	1	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	3	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	2	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	2	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	1	-	-	-	-	-
University of Rochester LAPS	3	-	-	-	5	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	6	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	6	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	1	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	1	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	28	15	47	3	44	17	3	3	1	3

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	CCTG-PR26	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	4	-
Audie L Murphy VA Hospital	-	-	49	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	26	-	1	3	-
Baylor College of Medicine/Comprehensive Cancer Cntr	-	-	-	-	-	29	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	1	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	33	-	16	-	-	-	7
Georgia CaRes	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	11	-	-	71	6	16	6	5
Hartford Hospital	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	1	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	2	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	4	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-	3	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Lahey Clinic	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	6	-	-	-	-
Malcom Randall Vets Administration Medical Center	-	-	-	-	-	-	-	-	-	-
Mass Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	-	2	-	3	-	17	-	-	1	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	2	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-	4	20	3	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	CCTG-PR26	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Northwestern University LAPS	-	-	-	-	-	-	-	-	4	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	2	-	15	18	-	32	-	-	-	7
Regents of the University of Michigan	-	-	-	-	-	-	-	-	1	-
Rhode Island Hospital	-	-	-	-	-	-	-	1	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	6	11	3
The Hawaii NCORP	-	-	2	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	-	-	-	3	11	9	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-	-	-	-	-	3	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	1	5	-	2	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	17	-	-	-	20	-	-	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	-	-	-	-	-	-	-	-	-
University of Arizona LAPS	-	-	-	-	-	-	-	1	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	-	-	-	-	-	4	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	1	-	-	2	-	-	17	13	2
University of Kentucky/Markey Cancer Center	-	-	-	-	4	15	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	2	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	6	-	7	-	4	4	-
University of Rochester LAPS	-	-	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	13	2	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	9	-	4	4	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	2	27	91	66	7	260	16	89	69	24

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	-
Audie L Murphy VA Hospital	-	-
Banner MD Anderson Cancer Center	-	-
Baylor College of Medicine/Comprehensive Cancer Cntr	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	-
Desert Regional Medical Center	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	1
Fred Hutchinson Cancer Research Center LAPS	-	10
Georgia CaRes	-	-
Georgia NCI Community Oncology Research Program	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	2	-
Hartford Hospital	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Instituto Nacional De Cancerologia	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Intermountain Medical Center	-	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	-	-
Lahey Clinic	-	-
Loyola University Medical Center	-	-
Malcom Randall Vets Administration Medical Center	-	-
Mass Vets Epidemiology Research & Information Center	-	3
Medical U of South Carolina NCORP Community Site	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-
Mount Sinai Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Nevada Cancer Research Foundation NCORP	-	-
Northwell Health NCORP	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGU012	NRGGU013
Northwestern University LAPS	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-
Sutter Cancer Research Consortium	1	-
The Hawaii NCORP	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	-	-
The West Clinic - Wolf River	-	-
Tulane University School of Medicine	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-
UC San Diego Moores Cancer Center	3	-
UCLA / Jonsson Comprehensive Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	-
University of Arizona LAPS	-	-
University of Arkansas for Medical Sciences	-	-
U of California Davis Comprehensive Cancer Center	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kentucky/Markey Cancer Center	-	-
University of Mississippi Medical Center	-	-
University of Nebraska Medical Center	2	-
University of Oklahoma Health Sciences Center LAPS	2	5
University of Rochester LAPS	-	-
University of Texas Health Science Center at San Antonio	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-
Virginia Mason Medical Center	-	-
Wayne State University/Karmanos Cancer Institute	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	10	19

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Robin Kamucheka
 Clinical Trial Program Manager: Sharon Palmer

Time/Location

Friday, October 9, 2026 9:00 a.m. - 11:00 a.m.

Room: Water Tower (Concourse Level)

Agenda

9:00 – 9:05 am Welcome & Immunotherapeutics Committee Update
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

9:05 – 9:20 am iMATCH Pilot Update: Stage II Update
 Siwen Hu-Lieskovan, Katerina Politi, Paul Swiecicki
S2101 Study Chairs

9:20 – 9:25 am Q & A

9:25 – 9:40 am Immunotherapeutic Strategies in Small Cell Lung
 Cancer - Anne Chi-An Chiang, MD, PhD
Executive Officer, Immunotherapeutics
Associate Cancer Center Director, Yale School of Medicine

9:40 – 9:50 am Q & A

9:50 – 10:15 am Second Talk TBD

10:15 – 10:25 am Alliance Immunotherapeutics Update
 Elad Sharon, MD, MPH
Associate Professor of Medicine
Dana-Farber Cancer Institute

10:25 – 10:35 am ECOG-ACRIN Immunotherapeutics Update
 Yana G. Najjar, MD
Associate Professor of Medicine, University of Pittsburgh
Director, Clinical and Translational Research Center

10:35 – 10:50 am Cancer Immune Monitoring and Analysis Center
 (CIMAC) Update - Cara Haymaker, PhD
*Associate Professor, University of Texas MD Anderson
 Cancer Center, MDA CIMAC Co-Lead*

10:45 – 10:55 am Panel Discussion

10:55 – 11:00 am Final Comments & Closing Remarks
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

Active Studies

S2101, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi.
 Activation: 10/14/22.

Immunotherapeutics Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S2101</i>
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	<i>1</i>
<i>Essentia Health NCI Community Oncology Research Program</i>	<i>1</i>
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	<i>5</i>
<i>Heartland Cancer Research NCORP</i>	<i>1</i>
<i>Michigan Cancer Research Consortium NCORP</i>	<i>1</i>
<i>Northwestern University LAPS</i>	<i>2</i>
<i>Pacific Cancer Research Consortium NCORP</i>	<i>1</i>
<i>Regents of the University of Michigan</i>	<i>16</i>
<i>The NCI Community Oncology Research Program: The New Mexico NCORP</i>	<i>1</i>
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	<i>6</i>
<i>University of Arkansas for Medical Sciences</i>	<i>5</i>
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	<i>12</i>
<i>ALLIANCE</i>	<i>22</i>
<i>ECOG-ACRIN</i>	<i>15</i>
<i>NRG</i>	<i>12</i>
<i>Total</i>	<i>101</i>

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer: Alex Herrera, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS
 Alejandro Hernandez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
 Radiation Oncology: Austin Sim, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Roula Bustami
 Cassie Villasin
 Oncology Research Professionals: Breanne Burke, BS
 Callie Wiskus, BS, CCRP
 Patient Advocate: Ashley Giacobbi
 Pharmaceutical Science: Holly O. Chan, PharmD
 Man Yee Merl, PharmD
 Protocol Project Manager: Amy Doyle
 Protocol Project Manager: Samantha Bankston (MyeloMATCH)
 Clinical Trials Program Manager: Sharon Palmer
 Clinical Trials Program Manager: Sarah Cantu (MyeloMATCH)

Time/Location

Friday, October 9, 2026 4:30 p.m. - 6:30 p.m.
 Room: Water Tower (Concourse Level)

Agenda

1. Updates in Leukemia Translational Medicine - Cecilia Yeung
2. MyeloMATCH - Laura Michaelis
3. MPN Trial - Alex Coltoff
4. ALL Updates - Kristen O'Dwyer
5. CLL Updates - Deborah Stephens and Mazyar Shadman

AML/MDS Studies

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

CTSU/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24; Complete: 10/01/2024.

ALL Studies

Active Studies

CTSU/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17; Reactivated: 02/26/2026.

Developing Studies

S2507, "A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD)." Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

S2701, "A Phase II Randomized Study Comparing Total Marrow and Lymphoid Irradiation (TMLI) with Fractionated Total Body Irradiation (FTBI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) in Patients with Acute Lymphoblastic Leukemia." Drs. M Al Malki, J. Wong, and S. Mokhtari.

Leukemia Committee

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/01/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients $\geq$ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients $\geq$ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 9/29/21.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20; Closed: 02/15/2026.

CLL Studies

Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov. Activated: 06/01/2026.

Closed Studies

CTS/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTS/A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ($\geq$ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

S2603 "A Phase II Study of Nuvisertib and Decitabine-Cedazuridine for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)." Drs. A. Coltoff, A. Gerds, and F. El Chaer.

MyeloMATCH

Active Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials." Drs. J. Radich and S. Jiwani. Activated: 05/16/24.

MM1YA-S01, "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial." Drs. P. Shami and T. Lin. Activated: 05/16/24.

MM10A-S03, "A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy." Drs. E. Huseilton and U. Borate. Activated: 04/01/25.

Leukemia Committee

MM10A-S04, “A Phase II Trial of ASTX727 with Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A myeloMATCH Substudy.” Drs. U. Borate and J. Jayanshu. Activated: 07/22/26.

CTSU/MM1MDS-A01, “A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study.” Dr. A. Patel. Activated 04/01/25.

CTSU/MM10A-EA02, “A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy.” Drs. J. Altman and A. Perl. Activated 06/06/24.

CTSU/MM1YA-A04, “Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy.” Dr. C. Ustun. Activated 05/08/26.

CTSU/MM1YA-CTG01, “A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy.” Drs. S. Assouline and L. Savoie. Activated 07/18/24.

Developing Studies

MM10A-S05, “A RAS-Activated Biomark Driven Phase II Study Evaluating the Addition of Tuspetinib to CPX-351 Induction Therapy in Older Fit Adults with Acute Myeloid Leukemia: A myeloMATCH Substudy.” Drs. J. Appelbaum, B. Jonas, and M. Konopleva.

MM1-S06, “A Phase II Study of Novel Agents with Venetoclax and the DNMT1 Inhibitor Cedazuridine-Decitabine for Newly Diagnosed Acute Myeloid Leukemia/Myelodysplastic Syndromes with TP53 Mutations (NAVIGATE-TP53): A myeloMATCH Substudy.” Drs. R. Shallis, E. Winer, D. Sallman.

CTP Studies

Active Studies

21CTP.LEUK01, “A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia” Drs. Advani, Liedtke, and Radich. Activation: 05/15/2025

26CTP.LEUK02, APEX-MF: “A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib for Treatment-Naïve, Cytopenic Myelofibrosis” Drs. Coltoff, Gerds, Borate, and Chen. Activation: 06/26/2026

Leukemia Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1905	S1925	MYELO MATCH	MM1YA- S01	MM10A- S03	MM10A- EA02	MM1YA- CTG01	21CTP LEUK01
Baptist Memorial Health Care/Mid South NCORP Consortium	-	1	9	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	2	9	-	-	-	-	-	1
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	6	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	5	-	1	2	1	-
Cedars-Sinai Medical Center	-	-	8	-	-	5	-	-
City of Hope Comprehensive Cancer Center	6	2	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	2	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	1	8	3	1	1	-	-
Essentia Health NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	4	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	15	-	-	-	-	-
Georgia CaRes	-	-	13	-	1	-	-	-
Heartland Cancer Research NCORP	-	-	8	-	-	-	-	-
Henry Ford Hospital	-	3	7	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	2	1	-	-	1	-	-
Loyola University Medical Center	-	1	12	-	1	3	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	5	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	5	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	7	24	1	1	-	-	-
Montana Cancer Consortium NCORP	-	-	3	-	-	-	-	-
Mount Sinai Hospital	-	-	3	2	-	-	1	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	19	3	-	-	-	-
Northwestern University LAPS	-	1	38	2	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	16	4	-	-	-	-
Oregon Health and Science University	1	-	6	1	-	-	-	-
Our Lady of the Lake Hospital	-	-	13	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	30	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	1	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	1	-	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	-	-	1	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	3	50	5	-	-	4	-
Tufts Medical Center	-	-	1	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	5	-	-	-	-	-	1
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	15	1	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	60	7	-	-	3	-
University of Arizona LAPS	-	1	6	1	1	1	-	-
University of California Davis Comprehensive Cancer Center	-	4	3	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	2	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	-	6	1	-	2	-	-
University of Nebraska Medical Center	-	-	7	1	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	-	1	5	-	1	-	-	-
University of Rochester LAPS	4	16	65	8	1	3	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	23	16	2	-	-	1	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	14	2	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	7	1	-	1	-	-
ALLIANCE	2	56	277	12	4	-	-	-
CCTG	-	16	75	-	-	-	-	-
COG	1	-	-	-	-	-	-	-
ECOG-ACRIN	2	21	260	18	5	-	-	-
NRG	-	6	50	2	2	-	-	-
Total	24	198	1,169	77	20	19	12	3

Leukemia Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A041501	A041703	A042001	EA9181	EA9213
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	4	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	3	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	4
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-
Georgia CaRes	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-
Houston Methodist Hospital	-	-	-	3	-
Intermountain Medical Center	2	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-
Loyola University Medical Center	-	-	-	3	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-
Northwestern University LAPS	3	-	1	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-
Oregon Health and Science University	8	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-
Stanford Cancer Institute Palo Alto	8	-	3	-	-
The Hawaii NCORP	-	-	-	4	-
The NCI Community Oncology Research Program: The New Mexico NCORP	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	-	-
Tufts Medical Center	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	3	1	-	12	-
UC San Diego Moores Cancer Center	-	-	-	2	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	1	-	2	-	-
University of Arizona LAPS	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	2	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	1	-	4	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-
University of Rochester LAPS	7	4	4	15	-
University of Utah - Huntsman Cancer Institute LAPS	1	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-	3	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	5	-	2	1	-
ALLIANCE	-	-	-	-	-
CCTG	-	-	-	-	-
COG	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	44	6	12	54	4

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Yingqi Zhao, PhD
 Mary Redman, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:

Biology/Pathology: Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD

Subcommittee Chairs:

Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Tina Cascone, MD, PhD
 Shirish Gadgil, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Lisa G. Davis, RN
 Patient Advocate: Barbara Martin, MS
 Pharmaceutical Science: Safae Ghouraichi, PharmD
 Michael Leung, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler, MA (Lung-MAP)
 Clinical Trials Program Manager: Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Friday, October 9, 2026 11:30 a.m. - 1:30 p.m.

Room: Regency A (Ballroom Level)

Agenda

General Updates & Announcements: Jhanelle E. Gray, MD

Upcoming Meetings and Deadlines

Keynote #1: AACR Plenary/WCLC Presidential Encore Presentation

Chad Rusthoven, MD

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Megan Daly, MD

Translational Medicine Session: Ignacio Wistuba, MD

Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN

Imaging: Chadwick Wright, MD

Patient Advocate Update: Barbara Martin, MS

Keynote #2: WCLC Encore Presentation: Maya Khalil, MD

Thoracic Medical Oncology: Jhanelle Gray, MD

S2409, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Activated: 9/8/25; Accrual Goal: 900; Accrual: 32. Anne Chiang, MD and Alberto Chiappori

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 14. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3983. Karen Reckamp, MD and David R. Gandara, MD

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 8/3/26. Dr. Jonathan Riess and Dr. Susan Scott

Lung Committee

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)." Activated: 9/27/24; Accrual goal: 88; Accrual: 18; 4 (revision 1). Shirish Gadgeel, MD and Christian Rolfo, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Activated: 4/28/25; Accrual Goal: 378; Accrual: 123. Saiama Waqar, MD, MSCI and Tina Li, MD

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 35; 28 (revision 1). Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 29. Paul Paik, MD and Xiuning Le, MD, PhD

Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Reckamp, Waqar, Redman, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab Hyaluronidase in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell

Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel. Activation: 9/27/24.

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Scott and Riess.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li. Activation: 4/28/25.

S2409, "PRISM: PReclisn in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang, Chiappori, Kim, et al. Activation: 9/8/25.

S2414, "A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients

Lung Committee

Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of

Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20. Permanently closed to accrual: 12/15/25.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20. Permanently closed to accrual: 2/15/26.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

Lung Committee

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local

Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A

Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and

Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and

Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900P, "A Randomized Phase II Selection Design of Sapanisertib and

Paclitaxel with or without Serabelisib in Participants with NRF2 or PI3K Pathway-Positive Stage IV or Recurrent Squamous Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Paik and Riano.

S1900Q, "A Phase II Study of Zongertinib and Trastuzumab Deruxtecan

in Participants with HER2-Positive Stage IV Non-Small Cell Lung Cancer (Alliance Lung-MAP Sub-Study)." Drs. Parikh and Doroshov.

S2608, "Sequencing of IMmunOtherapy and Chemoradiotherapy in

Unresectable Stage III Non-small Cell Lung Cancer: A Randomized Phase III Study (SIMON)." Dr. Park.

S2612, "A Phase II Study of Atezolizumab and JBI-802 for Previously Treated

Extensive Stage Small Cell Lung Cancer (SCLC)." Drs. Tseng and Puri.

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900G	S1900J	S1900K	S1933	S2409	S2414
Arnot Ogden Medical Center/Falck Cancer Center	7	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	48	6	3	-	1	1	1	-	2
Baylor College of Medicine/Duncan Comp Cancer Center	-	-	5	-	-	-	-	-	-
Boston Medical Center	-	-	7	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	2	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	4	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	59	1	-	-	-	-	4	-	-
Cancer Research of Wisconsin & N Michigan Consort	39	-	7	-	-	-	-	-	1
Carle Cancer Center NCI Comm Oncology Research Prgrm	3	-	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	2	-	-	-	-	-	-
Cedars-Sinai Medical Center	21	-	-	1	-	-	-	-	-
City of Hope Comprehensive Cancer Center	7	2	1	-	-	-	-	-	-
Columbia University NCI Comm Oncology Research Prgrm	13	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	28	-	6	-	-	-	-	-	-
CommonSpirit Health Research Institute	41	-	1	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	4	3	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	1
Essentia Health NCI Comm Oncology Research Program	18	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	8	-	-	4	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-
Georgia CaRes	6	-	1	-	-	-	1	-	-
Georgia NCI Community Oncology Research Program	83	8	3	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	1	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	20	-	3	-	-	-	-	-	-
Hartford Hospital	4	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	160	2	9	-	-	-	5	-	-
Henry Ford Hospital	20	-	-	-	-	-	1	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	1	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	8	-	-	-	-	-	-
Intermountain Medical Center	1	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgam	97	1	-	-	-	1	-	-	-
Kansas City Veterans Affairs Medical Center	5	1	-	-	-	-	-	-	-
Lahey Clinic	35	-	-	-	-	-	2	-	1
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-
Loyola University Medical Center	28	2	-	-	-	-	-	1	-
Malcom Randall Veterans Administration Medical Cntr	23	1	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Info Cntr	66	1	4	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	28	-	-	1	-	-	-	1	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	131	2	4	2	-	-	-	1	-
Mission Hospital	1	-	-	-	-	-	-	-	-
Moffitt Cancer Center	23	1	1	1	-	2	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900G	S1900J	S1900K	S1933	S2409	S2414
Montana Cancer Consortium NCORP	10	-	1	-	-	-	1	-	-
Mount Sinai Braman Comprehensive Cancer Center	2	-	-	-	-	-	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-
Northwestern University LAPS	39	4	1	2	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	2	-	-	-	-	1	-	-	-
Oregon Health and Science University	14	-	-	1	-	2	-	-	1
Our Lady of the Lake Hospital	4	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-	1
Salem Hospital	7	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	57	-	8	-	-	1	-	1	1
Sutter Cancer Research Consortium	79	-	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	13	-	-	-	-	-	-	-	-
The Hawaii NCORP	29	-	2	-	1	-	-	-	-
The Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-	-
The NCI Comm Oncology Research Prgrm: The New Mex NCORP	119	-	1	-	-	-	1	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	113	3	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cncr Cntr	32	2	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	18	1	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	98	3	12	-	-	-	6	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	7	-	-	-	-	-	-
University of Arizona LAPS	1	1	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	49	3	1	1	-	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	1	1	1	-	-	-
University of Kentucky/Markey Cancer Center	67	7	1	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	38	5	1	-	-	-	18	-	-
University of Rochester LAPS	68	-	-	-	-	2	-	1	-
University of Texas MD Anderson Cancer Center LAPS	3	-	7	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	3	2	4	-	-	1	-	-	-
Upstate Carolina Consort Comm Oncology Research Prgrm	42	-	3	-	-	-	-	-	1
Wayne State University/Karmanos Cancer Institute	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	45	-	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	34	4	5	4	-	-	-	-	-
ALLIANCE	942	23	29	3	1	4	5	-	-
CCTG	-	-	39	-	-	-	-	-	-
ECOG-ACRIN	410	12	11	2	-	11	-	3	1
NRG	548	10	89	3	-	1	2	1	-
Total	4,036	111	304	27	4	29	48	9	10

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A081801	A082002	A151216	EA5162	EA5182	EA5221	EA5231	NRGLU008	S2402
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	1	-	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	4	-	26	-	2	-	-	2	1
Baylor College of Medicine/Duncan Comp Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	3	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	25	-	59	-	1	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	5	-	-	-	-	-	-
Columbia University NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	2	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	3	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	8	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	1	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	15	3	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-
Georgia CaRes	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	10	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	1	-	1	-	-	-	-	-	1
Hartford Hospital	-	-	-	-	2	-	1	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	2	-	44	1	-	-	-	-	-
Houston Methodist Hospital	-	-	8	-	2	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	1	-	3	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgam	7	-	208	-	8	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	1	-	-	-
Lahey Clinic	1	-	30	-	-	-	1	-	-
Loma Linda University Medical Center	-	-	10	-	-	-	-	-	-
Loyola University Medical Center	2	-	26	-	-	-	-	-	-
Malcom Randall Veterans Administration Medical Cntr	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Info Cntr	13	-	34	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	11	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	28	-	83	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A081801	A082002	A151216	EA5162	EA5182	EA5221	EA5231	NRGLU008	S2402
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	1	-	3	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	8	-	24	-	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	4	-	-	-	-	-	-
Regents of the University of Michigan	-	-	51	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	1	11	-	-	-	-	3	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-
The Brown Cancer Center at University of Louisville	-	-	5	-	-	-	-	-	-
The NCI Comm Oncology Research Prgrm: The New Mex NCORP-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	1	-	31	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cncr Cntr	-	-	15	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	5	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	12	-	-	-	-	-	-
University of Arizona LAPS	-	-	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	1	-	-	-
U of California Davis Comprehensive Cancer Center	1	2	46	-	1	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	-	24	-	1	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	58	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	1	5	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	26	-	-	-	-	-	-
University of Nebraska Medical Center	1	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	5
University of Rochester LAPS	-	-	-	-	-	2	-	-	1
University of Texas MD Anderson Cancer Center LAPS	-	-	2	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	1	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	1	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	7	-	57	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	109	4	986	4	26	4	2	5	8

Lymphoma Committee

Leadership

Chair: Sonali M. Smith, MD
 Vice-Chair: Jennifer E. Amengual, MD
 Executive Officer: Alex Herrera, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Thiruvengadam, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Adolescent & Young Adults: Boyu Hu, MD
 Cancer Control: TBD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Dawud Nael Dawud Ellayan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers, MS
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 8, 2026 5:00 p.m. - 7:00 p.m.
 Room: Regency C (Ballroom Level)

Agenda

Welcome & Introductions - Sonali Smith, MD & Jennifer Amengual, MD

A Note from Our Patient Advocate - Tricia Hernandez, MS

The Future of DLBCL: Are We There Yet?

1. Evolving strategies in 1L DLBCL: precision vs. targeted treatment - Patrick Reagan, MD
2. SWOG approach to RR DLBCL - Brian Hess, MD & Jennifer Amengual, MD
3. Is ctDNA ready for primetime in DLBCL? - Jeff Cherng, MD

SWOG Trial Updates

- | | | |
|----|-------|-----------------------|
| 1. | S1918 | Elizabeth Brem, MD |
| 2. | S2114 | Brian Hess, MD |
| 3. | S2207 | Jennifer Amengual, MD |
| 4. | S2308 | Nilanjan Ghosh, MD |
| 5. | S2506 | Boyu Hu, MD |
| 6. | S1925 | Debbie Stephens, DO |
| 7. | S2504 | Mazyar Shadman, MD |

Open Studies From Other Groups

- | | | |
|----|---------|-----------------------|
| 1. | A051902 | Jennifer Amengual, MD |
| 2. | A052101 | Tyler Phillips, MD |
| 3. | EA4232 | Marc Hoffmann, MD |

Good Hang with AYA: Ongoing Collaborations Between COG and SWOG

Sharon Castellino, MD & COG Colleagues

Active Studies

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. B. Hess and N. Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/2023.

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. N. Ghosh and J. Friedberg. Activated: 8/1/2024.

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. B. Hu, B. Hu, and S. Smith. Activated: 8/10/2026.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 09/08/2023.

Lymphoma Committee

CTSU/AHOD2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 04/28/2023.

CTSU/EA4232, "A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Response (CR1) Following Induction Therapy (PTCL-STAT)." Dr. Bennani. SWOG Champion: Dr. M. Hoffmann. Activated: 1/30/2025.

Closed Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/2024.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. E. Brem and S. Smith. Activated: 3/19/21. Closed: 4/24/26.

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/2021. Closed: 5/28/25.

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17. Closed 10/3/24.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients $\leq$ 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023.

Active Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. D. Stephens. Activated: 12/14/20.

S2504, "A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants with Previously Untreated Richter Transformation (PIRAMID)." Drs. M. Shadman, D. Stephens, and A. Danilov. Activated: 6/1/2026.

Closed Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. V. Shankaran. Activated 7/26/2021. Closed 12/16/2024.

Lymphoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1918	S2114	S2207	S2308	A051902	A052101	AH02131
Baptist Memorial Health Care/Mid South NCORP Consortium	1	2	-	1	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	1	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	5	-	-	-	-	5
Cancer Research for the Ozarks NCORP	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	2	-	3	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	14	-	17	-	-	-
Cedars-Sinai Medical Center	1	-	6	2	-	-	3
City of Hope Comprehensive Cancer Center	11	-	-	16	-	-	22
Columbia University NCI Community Oncology Research Program	6	10	2	-	3	-	1
Dartmouth College - Dartmouth Cancer Center LAPS	-	2	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	8	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	7	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	6	-	9	-	-	-
Georgia CaRes	2	-	-	1	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	2	-	-	-
Henry Ford Hospital	-	1	-	2	-	-	3
Intermountain Medical Center	1	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	-	-	2	-	-	11
Kansas City Veterans Affairs Medical Center	-	-	-	1	-	2	-
Loyola University Medical Center	-	2	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	3	24	-	5	-	1	2
Michigan Cancer Research Consortium NCORP	8	-	1	1	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	1	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	6	-	-	-
Oregon Health and Science University	-	6	-	8	-	-	6
Pacific Cancer Research Consortium NCORP	-	13	1	4	-	-	1
Regents of the University of Michigan	-	-	-	3	-	-	-
Rhode Island Hospital	-	-	-	1	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	14	-	-	-
The Hawaii NCORP	1	-	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	11	1	23	-	5	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	1	-	2	-	-	1
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	9	-	-	-
University of Arizona LAPS	-	5	-	4	-	-	-
University of Arkansas for Medical Sciences	-	14	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	1	-	-
University of Colorado Cancer Center LAPS	-	-	-	11	-	-	1
University of Nebraska Medical Center	-	-	-	-	-	2	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	2	-	-	-
University of Rochester LAPS	-	13	9	25	8	20	33
University of Texas Health Science Center at San Antonio	-	-	2	1	-	-	1
University of Texas MD Anderson Cancer Center LAPS	-	-	-	24	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	12	-	1	11	-	-	13
Upstate Carolina Consortium Community Oncology Research Program	1	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	7	-	1	-	3	2
Wisconsin NCI Community Oncology Research Program	2	-	-	3	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	1	1
ALLIANCE	42	64	7	70	-	-	-
ECOG-ACRIN	17	19	-	53	-	-	-
NRG	7	12	5	26	-	-	-
Total	136	233	39	370	19	35	107

Lymphoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	ANHL1931	EA4231	EA4232
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-
Cedars-Sinai Medical Center	1	-	-
City of Hope Comprehensive Cancer Center	15	-	-
Columbia University NCI Community Oncology Research Program	3	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia CaRes	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-
Northwestern University LAPS	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
The Hawaii NCORP	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-
University of Arizona LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	1	-
University of Colorado Cancer Center LAPS	-	-	-
University of Nebraska Medical Center	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	10	-	2
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	33	1	2

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Hagen Kennecke, MD
 Statisticians: Michael Wu, PhD
 Megan Othus, PhD
 James Moon, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: William Carson, MD
 Radiation Oncology: TBD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: TBD
 Imaging: TBD
 Medical Oncology: TBD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: TBD
 SWOG's ECOG Liaisons: Sunandana Chandra, MD
 G. Paul Wright, Jr., MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Michael Lowe, MD

Designates

Adolescent & Young Adults: Leah Winer, MD
 Cancer Control: Sancy Leachman, MD, PhD (Prevention)
 Data Coordinator: Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals: Barbara J. Lomasney, RN, OCN
 Kathryn Allen, BA, CCRP
 Patient Advocate: Sara Selig, MD
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Stephanie Elise Trexler, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, October 10, 2026 11:30 a.m. - 1:30 p.m.
 Room: Regency D (Ballroom Level)

Agenda

11:30 - 11:45 am **Welcome & Updates** - Sapna Patel, MD

11:45 - 12:30 pm **Keynote Speaker: "Landscape and Chronology of Melanoma Metastasis"** - Roger Lo, MD, PhD

12:30 - 1:00 pm **Liaison Updates**

Updates from Adolescent and Young Adult Committee
 Leah Winer, MD

Updates from Prevention Committee - Soo Park, MD

Developing Studies

S2601, "Multicenter Selective Lymphadenectomy Trial – III: A randomized phase 3 noninferiority trial of selective lymphadenectomy of index lymph nodes vs. full therapeutic lymphadenectomy in patients with stage III melanoma achieving major pathologic response to neoadjuvant immunotherapy". Dr. Faries

S2616, "A randomized phase 3 study of anti-PD1, retifanlimab, vs. standard of care observation in patients with subclinical Merkel Cell Carcinoma as evidenced by positive ctDNA after curative-intent treatment with no clinical evidence of disease; the TOMMORROW trial; Treatment on Merkel MOlecular Recurrence Without clinically evident disease". Dr. Nghiem

S2617, "PRIMER: Phase III Trial of Botensilimab and Pembrolizumab in Resectable Melanoma". Dr. Sharon

Closed Studies

A091903, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023. Registration to Arm 3 is Temporarily Closed to Accrual as of 06/16/2025. Closed to Accrual as of 06/04/2026

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015. Closed to accrual as of 1/8/2026.

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22. Closed to accrual as of 8/28/2025.

Melanoma Committee

CTSU/EA6192, "The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020. Closed to accrual as of 9/3/2025.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPh Activated: 02/18/2020. Closed: 09/23/2022.

Melanoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2015	A091903	EA6141	EA6192	EA6194
Banner MD Anderson Cancer Center	39	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	112	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-
Cedars-Sinai Medical Center	30	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	3	-	-
Columbia University NCI Community Oncology Research Program	9	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	20	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	15	-	-	-	-
Georgia NCI Community Oncology Research Program	11	-	-	-	-
Intermountain Medical Center	44	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	31	-	-
Medical University of South Carolina NCORP Community Site	20	-	-	-	-
Moffitt Cancer Center	58	-	-	-	-
Northwell Health NCORP	10	-	-	-	-
Northwestern University LAPS	46	-	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	36	-	-	3	-
Regents of the University of Michigan	26	-	1	-	-
Sutter Cancer Research Consortium	-	-	7	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	7	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	48	-	3	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	4	-	3
USC Norris Comprehensive Cancer Center LAPS	5	1	-	-	-
University of Arizona LAPS	-	-	-	1	1
University of Arkansas for Medical Sciences	7	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	-	-
University of Kentucky/Markey Cancer Center	13	-	-	-	-
University of Nebraska Medical Center	4	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-
University of Rochester LAPS	7	-	13	-	-
University of Texas Health Science Center at San Antonio	3	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	23	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	33	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	16	-	-	-	-
Yale University - Yale Cancer Center LAPS	29	-	8	-	-
ALLIANCE	132	-	-	-	-
ECOG-ACRIN	228	-	-	-	-
NRG	102	-	-	-	-
Total	1,158	1	78	10	4

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa A. Kachnic, MD
 Executive Officer: Lisa A. Kachnic, MD
 Statisticians: Sam Callis, MS

Liaisons

Breast Committee: Eileen P. Connolly, MD
 Cancer Care Delivery Committee: Eileen P. Connolly, MD
 Prevention, Screening & Surveillance Cmte: Eileen P. Connolly, MD
 CNS Working Group: Tony Wang, MD
 Gastrointestinal Committee: David Horowitz, MD
 Genitourinary Committee: James Yu, MD
 Immunotherapeutics Committee: Robert Samstein, MD, PhD
 Leukemia Committee: Austin Sim, MD
 Lung Committee: Henry Park, MD
 Lymphoma Committee: Nicholas B. Figura, MD
 Melanoma Committee: Evan Wuthrick, MD
 Myeloma Committee: Chelsea Pinnix, MD, PhD
 Sarcoma Working Group: Jeremy Harris, MD
 Symptom Management & Survivorship Cmte: Erin Gillespie, MD, MPH

Designates

Theranostics Subcommittee Chair: Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chair: Jeremie Calais MD, PhD
 Theranostics Subcommittee Vice-Chair: Tanya Dorff, MD
 Data Coordinator: Larry Kaye
 Sr. Protocol Coordinator: Kali Nicks
 Clinical Trials Program Manager: Sarah Cantu

Time/Location

Thursday, October 8, 2026 4:00 p.m. - 6:00 p.m.

Room: Comiskey (Concourse Level)

Agenda

4:00 - 4:05 pm	Welcome - Chul S. Ha, MD
4:05 - 4:10 pm	Report from Executive Officer - Lisa Kachnic, MD
4:10 - 4:15 pm	Update from IROC - TJ FitzGerald, MD
4:15 - 4:20 pm	Update from NCI - Bhadrasain Vikram, MD
4:20 - 4:30 pm	Advancing SWOG Palliative Care Concept - Robert Krouse, MD & Marie Bakitas, DNSc

4:30 - 4:40 pm	Artificial Intelligence-based targeting platform for recruiting cancer clinical trial participation - Nadine Housri, MD
4:40 - 5:00 pm	SLOW ROLL: <u>Sa</u> Lvage radiation <u>Or</u> <u>W</u> atchful waiting, <u>Re</u> imaging up <u>On</u> e <u>L</u> evated <u>L</u> abs with delayed salvage - Martin Ma, MD, PhD
5:00 - 5:20 pm	Treating Ultra-low Estrogen-positive breast cancer: Surveillance vs endocrine Therapy (TRUE-STAR) - Shraddha Dalwadi, MD, MBA
5:20 - 5:40 pm	S2427, "Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) - Leslie Ballas, MD
5:40 - 6:00 pm	Esophageal protocol concept - Russell Palm, MD
6:00 pm	Closing Remarks - Chul S. Ha, MD

Publication List by Committee

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle.

Submitted Manuscripts

None this cycle.

ADVANCED PRACTICE PROVIDERS AND NURSE SCIENTISTS COMMITTEE

Published/Accepted Manuscripts

Integrating Oncology APPs and Clinical Pharmacists into Clinical Cancer Research. Braun-Inglis C, Myers J, O'Brien B, Kottschade L, Flannery M, DeTroye AT, Elko T, Leatherwood A, Mader A, Wong SF, Foust M, Bakitas M, Benson AB, Berenberg JL, Primeaux B, Rosenzweig M, Demirhan K, Statler T, Vogel W, Sun V. *Journal of the National Cancer Institute*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42015388/>

Nurse scientist and advanced practice registered nurse contributions to oncology clinical trials within the National Cancer Institute Cooperative Group infrastructure. Myers JS. *Asia-Pacific Journal of Oncology Nursing*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42388225/>

Submitted Manuscripts

None this cycle.

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

S0777 Interim Analysis in Clinical Trials: Caution Against Premature Conclusions – The SWOG Multiple Myeloma S0777 Case Study. Goren E, Sexton R, Orlowski R, Hoering A. *Trials*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42661196/>

Submitted Manuscripts

None this cycle.

BREAST COMMITTEE

Published/Accepted Manuscripts

S1007 Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER). Kalinsky K,

Barlow WE, Puri R, Mitra A, Home T, Gralow J, Albain K, Hayes D, Delaloge S, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstein F, Sharma P, Puszta L, Thompson A, Pathak H, Godwin A. *Annals of Oncology*. 2026.

<https://pubmed.ncbi.nlm.nih.gov/42613139/>

S1706 Acute Toxicity in SWOG 1706, a Randomized Trial Comparing Radiotherapy with and without Concurrent Olaparib for Inflammatory Breast Cancer. Jaggi R, Meisner A, Chalasani P, Barlow WE, Bellon JR, Henry NL, Lew D, Matuszak MM, Moran JM, Pierce LJ, Rakovitch E, Reyes SJ, Speers C, Unger JM, White JR, Woodward WA, Zellars RC, Puszta L, Sharma P. *Journal of Radiation Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42520859/>

S1007 Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007). Abdou Y, Hoag J, Barlow WE, Albain KS, Gralow JR, Meric-Bernstam F, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Schott AF, Racz J, Baehner FL, Tripathy D, Hortobagyi GN, Puszta L, Sharma P, Kalinsky K. *Journal of the National Cancer Institute*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42458791/>

Submitted Manuscripts

None this cycle.

CANCER CONTROL AND PREVENTION

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

Multiple Studies Federal and Industry Sponsorship in US Cancer Clinical Trials. Unger JM, Xiao H, LeBlanc M, Hershman DL. *JAMA Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42623089/>

S1415CD Impact of Primary Prophylactic Colony-Stimulating Factor Delivery Method on Febrile Neutropenia: Secondary Analysis of a Pragmatic Cluster Randomized Clinical Trial. Shih LC, Arnold K, Bansal A, Bell-Brown A, Watabayshi KK, Hershman DL, Ramsey SD. Accepted 2026.

Multiple Studies Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review. Xiao H, LeBlanc M, Bertagnolli M, Threlkel S, Chansky M, Hershman DL, Unger JM. *JAMA Network Open*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42518232/>

Multiple Studies Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants. Gupta A, Till

Publication List by Committee

C, LeBlanc ML, Hershman DL, Unger JM. *JCO Oncology Practice*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41921118/>

Submitted Manuscripts

Multiple Studies Decreasing Enrollment in NCI-sponsored Trials Over Time Among Rural and Frontier Patients with Cancer. Okado I, Till C, Osarogiagbon R, Doolittle G, Hershman DL, Unger JM. Submitted 2026.

PALLIATIVE CARE COMMITTEE

Published/Accepted Manuscripts

S2408 Lanreotide for the prevention of postoperative pancreatic fistula (SWOG 2408): study protocol for a multicenter randomized controlled trial. Intara AS, Guthrie KA, Chauhan SSB, Arnold K, Topacio R, Carvalho K, Garcia A, Fraser V, Wright GP, Sun V, Ahmad SA, Rocha FG, Ecker BL, Reames BN, Karanickolas P, Krouse RS, Pillarisetty VG, Sham JG. *Trials*. 2026. <https://doi.org/10.1186/s13063-026-09933-8>

Submitted Manuscripts

None this cycle.

PREVENTION, SCREENING AND SURVEILLANCE COMMITTEE

Published/Accepted Manuscripts

S9217 Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model. Vertosick EA, Goodman P, Tangen CM, Till C, Thompson IM, Lucia MS, Eastham J, Lilja H, Vickers AJ. *European Urology Focus*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41864782/>

S9217 No Evidence of Post-Finasteride Syndrome in 267,983 person-years follow-up in the Prostate Cancer Prevention Trial. Till C, Tangen C, Goodman P, Unger Thompson Jr. IM. *Urology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42628582/> In press.

S1904 Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. Crew K, Anderson GL, Arnold K, Dzingle SA, Michel A, Delucie M, Law C, Pruthi S, Leon ACS, Shirley R, Gross-Perdekamp MT, Colanna S, Krisher Stacy, King T, Yee L, Ballinger T, Braun-Inglis C, Mangino D, Wisinski L, DeYoung CA, Ross M, Floyd J, Kaster A, Vanderwalde L, Saphner T, Zarwan CL, Lo S, Graham C, Conlin AK, Butler KY, Agnese DM, Jernigan C, Hershman DL, Neuhouser ML, Zell JA, Arun B, Kukafka R. *Journal of the National Cancer Institute*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42391096/>

Submitted Manuscripts

None this cycle.

SYMPTOM MANAGEMENT AND SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

NRG-GI004/S1610 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Lima CMSPR, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil MF, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. *Journal of Clinical Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42525921/>

A221504 Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Gupta P, Gupta K, Dockter T, Harlos E, Chow S, Subbiah N, Ruddy K, Bazhenova L, Terstriep S, Huang C, Kratzke R, Vokes E, Loprinzi C. *Cancers*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41681846/>

S1600 Flow cytometry method to identify arginase-1 expressing MDSCs. Srinivasan P, Bechtel M, Wyczzechowska D, Ochoa A, Fisch M, Henry NL, Unger JM, Hamilton-Reeves J. *MethodsX*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42233054/>

S1600 Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. Hamilton-Reeves JM, Unger JM, Holzbeierlein JM, Lew DL, Ryan MJ, Daneshmand S, Lerner SP, Kukreja JEB, Lee E, Tabayoyong WB, Hershman DL, Fisch MJ, Henry NL. *JAMA Network Open*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42475098/>

S1706 Acute Toxicity in SWOG 1706, a Randomized Trial Comparing Radiotherapy with and without Concurrent Olaparib for Inflammatory Breast Cancer. Jaggi R, Meisner A, Chalasani P, Barlow WE, Bellon JR, Henry NL, Lew D, Matuszak MM, Moran JM, Pierce LJ, Rakovitch E, Reyes SJ, Speers C, Unger JM, White JR, Woodward WA, Zellars RC, Pusztai L, Sharma P. *Journal of Radiation Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42520859/>

S1714 Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714. Trivedi M, Unger J, Henry NL, Darke A, Hertz D, Brannagan T, Reyes S, Schneider B, Irvin W, Hathaway A, Vander Woude A, Gudena V, Cabrera-Galeana P, Orsted M, LeBlanc M, Fisch M, Hershman D. *JAMA Network Open*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41961500/>

Publication List by Committee

Multiple Studies Comparison of five definitions of meaningful change on patient-reported outcomes in four SWOG clinical trials. Jones SMW, Till C, Unger JM, Hershman DL, Henry NL, Berry DL, Patel S, Hall E. *Journal of Patient Reported Outcomes*. 2026. <https://doi.org/10.1186/s41687-026-01182-2>. In press.

S1105 The impact of intervention-induced symptom awareness on patient reported outcomes in a randomized mobile health intervention for medication adherence in cancer care. Hershman DL, Till C, Jones S, Fisch M, Henry NL, Unger JM. *Advances in Patient-Reported Outcomes*. 2026. <https://doi.org/10.1016/j.apro.2026.100344>

Submitted Manuscripts

S1714 Vitamin D Insufficiency and Risk of Taxane-Induced Peripheral Neuropathy: Results from SWOG S1714. Nguyen-Hoang N, Unger JM, Darke A, Fisch MJ, Henry NL, Hershman DL, Trivedi MS, Hertz DL. Submitted 2026.

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Chae YK, Othus M, Patel S, Backes F, O'Malley D, Cristea M, Naing A, Kurnit K, Eskander R, Goodrich S, Robinson W, Kim H, Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. *Journal for the ImmunoTherapy of Cancer*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41672597/>

S1609 Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). Chae YK, Othus M, Lyu J, Lee S, Paik S, Dietrich E, Jung CM, Chung LI, Patel S, Kurzrock R. *Journal for ImmunoTherapy of Cancer*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41819545/>

S1609 DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers. Patel SP, Othus M, Chae YK, Azenkot TA, Alviz C, Threlkel S, Haymaker C, Streicher HZ, Magner CM, Chen HX, Sharon E, Ryan CW, Blanke CD, Kurzrock R. *Annals of Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41997295/>

S1609 A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results. Chae YK, Czeskleba J, Patel SP, Mentor A, Robinson W, Jones NL, Rampurwala M, Naing A, Beck JM, Moloney-Lineen C, Chung LI, McLeod CM, Chen HX, Sharon E, Threlkel S, Othus M, Ryan CW, Blanke CD, Kurzrock R. *Journal of Gynecologic Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41995270>

S1609 A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort. Chae YK, Sun R, Patel SP, Giles F, Ohr JP, Worden FP, Suga JM, Naing A, Cohen EE, Wallace J, Kang HS, Fenton S, Chung LY, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Othus M, Blanke CD, Kurzrock R. *Therapeutic Advances in Medical Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42499790/>

Submitted Manuscripts

S1609 Outcomes of Adolescent and Young Adult (AYA) Patients versus Patients Ages 40 and Older with Rare Solid Tumors Treated with Nivolumab plus Ipilimumab (NCI/SWOG S1609: DART trial). Othus M, Davies M, Alviz C, Chae YK, Patel SP, Kurzrock R. Submitted 2026.

S1609 Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609). Wang Y, Othus M, Chae YK, Davies M, Dietrich E, Patel SP, Kurzrock R. Submitted 2026.

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

A021502 Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. *New England Journal of Medicine*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41880612/>

NRG-GI004/S1610 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Lima CMSPR, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil MF, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. *Journal of Clinical Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42525921/>

Submitted Manuscripts

C80702 Prognosis-Informed Phenotype Assignment: A Novel In-Situ Single-Cell Analysis Method for Phenotype Discovery. Lau M, Vayrynen J, Haruki K, Ma C, Vayrynen S, Ugai T, Gu S, Borowsky J, Zhao M, Arima K, Dias Costa A, Shields A, Innocenti F, KitTan W, Shi Q, Giannakis M, Fuchs C, Yu K, Nowak J, Ogino S. Submitted 2025.

S2001 Randomized Phase II Trial of Olaparib Plus Pembrolizumab Versus Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer

Publication List by Committee

with Germline BRCA1/2 Mutations: SWOG S2001. Chung V, Guthrie KA, Pishvaian MJ, Lowy A, Sohal DSS, Colby S, Reiss KA, Khan G, Winograd R, Meyerhardt J, O'Reilly E, Chiorean EG, Philip PA. Submitted 2026.

GENITOURINARY COMMITTEE

Published/Accepted Manuscripts

S1314 Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. Zadoroznyj A, Eriksson P, Bernardo C, Tran L, Mattsson CA, Flaig T, Tangen C, Lerner S, McConkey D, Hoglund M, Leidberg F, Sjodahl G. *NPJ Precision Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42399473/>

S1806 INTACT (SWOG/NRG S1806) Phase III randomized trial of concurrent Chemoradiotherapy with or without Atezolizumab in localized muscle invasive bladder cancer. Trial design, eligibility criteria, patient enrollment characteristics and central review of clinical stageSingh P, Plets M, Efstathiou J, Jhavar SG, Tangen CM, Delacroix Jr S, Marquette C, Khalil MF, Scher K, Sachdev S, Johnson III BA, Jani A, Cross B, Grivas P, Palopoli J, Kirchner A, Shen X, Parikh M, Olson A, Mehan P, Feng F, Costello B, Joshi M, Daneshmand S, Petrylak D, Thompson I, Nguyen PL, Lerner SP. Accepted 2026.

Submitted Manuscripts

S1216 Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Submitted 2025.

S9346 Evaluating Survival Post-7-Month PSA Response, Stratified by Response, Disease Extent, and Intermittent vs. Continuous ADT in Metastatic Hormone-Sensitive Prostate Cancer: The S9346 Trial. Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Ong M, Swami U, Aggarwal N, Thompson I, Lerner S. Submitted.

Multiple Studies Practice Patterns in Metastatic Hormone-Sensitive Prostate Cancer: A Survey of North American Cooperative Group Oncologists. Breen P, Chalker C, Ong M, Anya O, McKay R, Carducci M, Kyriakopoulos C, Schweizer M, Haas N, Mandl A, Tangen C, Gulati S, Keim M, Lerner S, Ryan C, Ng R, Dorff T, Sokolova A. Submitted.

S1602 A Phase III Randomized Trial to Evaluate BCG Strain Differences and Priming for Bladder Cancer. Svatek RS, Tangen C, Meeks JJ, Gilbert SM, Lotan Y, Tyson M, Crispen P, Delacroix SE, Gills J, Daneshmand S, Woods M, Master VA, Mark JR, Alva ASA, Bangs R, Nakagawa D, Unger JM, Plets M, Thompson Jr IM, Lerner SP. Submitted 2026.

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

None this cycle.

Submitted Manuscripts

None this cycle.

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

C10403 Long-Term Follow-up of an Intensive Pediatric Regimen for Adolescents/Young Adults with Ph-negative Acute Lymphoblastic Leukemia: 10-year Survival Following CALGB 10403 (Alliance). Silva W, Yin V, Liedtke M, Claxton D, Fulton N, Giri S, Malnassy G, Mrozek K, Paietta E, Mullighan C, Larson RA, Stone R, Uy G, Luger S, Advani A, Stock W. *Blood Advances*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42101912/>

Submitted Manuscripts

None this cycle.

LUNG COMMITTEE

Published/Accepted Manuscripts

LUNGMAP Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Druce KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono DE, Leighl NB, Li BT, Li T, Mack PC, Neal JW, Paik PK, Patel SP, Riess JW, Redman MW, Reckamp KL. *Journal of Clinical Oncology* [Comments and Controversies]. 2026. <https://pubmed.ncbi.nlm.nih.gov/42234933/>

S1914 A Randomized Phase III Trial of Induction and Consolidation Atezolizumab with Stereotactic Body Radiation Therapy versus Radiation Alone in High Risk, Early-Stage Non-Small Cell Lung Cancer (SWOG/NRG S1914). Daly ME, Simone II SB, Redman MW, Hsieh M, Hesketh PJ, Hu C., Monjazeb AM, Steuer CE, Ganti AK, Kashani R, Bauman JR, Feliciano JL, Moon J, Ku K, Le-Lindqwister N, Baschnagel AM, Maraboyina S, Sherwood GB, Almquist D, Higgins KA, Gray JE, Bradley JD, Kelly K. Accepted 2026.

Submitted Manuscripts

S0424 Exposures, Tumor Factors and Survival by Sex and Smoking Status in Non-Small Cell Lung Cancer A Prospective Case-Series Trial (SWOG S0424, NCI NCTN). Albain K, Moon J, Ambrosone C, Darke A, Hsieh M, Santella R, Cheng TYD, Holland W, Borczuk A, Chay CH, Morris

Publication List by Committee

PT, Vallieres E, Kratzke R, Molina JR, Kolesar JM, Chen Y, Matsumoto S, Reid M, Zirpoli G, Davis W, Ondracek R, Bshara W, Omilian A, Gray J, Kelly K, Lara PN, Redman M, Gandara D, Mack P. Submitted 2025.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S1001/Others Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma. Chen Z, Luan D, Jørgensen RRK, Jakobsen L, Maurer MJ, El-Galaly TC, Nastoupil LJ, Cerhan JR, Flowers CR, Link BK, Lossos IS, Stephens DM, Cohen J, Habermann TM, Nowakowski G, Bartlett N, Friedberg JW, Kahl BS, Leonard JP, Brown P, Smedby KE, Jerkeman M, Martin P. *American Journal of Hematology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42240061/>

S1826 Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Ahmed S, Li H, Herrera AF, Perry AM, Kovach AE, Rutherford SC, Davison K, Castellino SM, Evens AM, Kahl B, Bartlett NL, Leonard JP, Shipp MA, Smith SM, Kelly KM, LeBlanc M, Friedberg JW, Song JY. *Blood Advances*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42526889/>

S1826 Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma. Goyal G, Lurain K, Lopez G, Rutherford SC, Castellino S, Davison K, Evens A, Smith SM, Kelly K, LeBlanc M, Song JY, Odeny T, Ratner L, Friedberg JW, Herrera AF. *JCO Oncol Adv*. 2026 Jan;3(1):e2500143. doi: 10.1200/oa-25-00143. Epub 2026 Feb 26. <https://pubmed.ncbi.nlm.nih.gov/42577949/>

Submitted Manuscripts

None this cycle.

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S1616 Cellular Neighborhoods Govern Antitumor T-Cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. Campbell KM, Chen DG, Bustami ZE, Naser Al Deen NN, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo IP, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi A, Victor AI, Margolin K, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu M, Scumpia PO, Ribas A. *Cancer Discovery*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42013417/>

Submitted Manuscripts

S1512/S1616 Desmoplastic Melanoma Spatial Atlas Reveals Programs of Immunotherapy Response. Daniel G, Truong A, Naser Al Deen N, Gonzalez CR, Medina E, Baselga Carretero I, Chen JM, Kuklinski LF, Eroglu Z, Hu-Lieskovan S, Chmielowski B, Truong TG, Khushalani NI, Ikeguchi AP, Victor AI, Margolin K, Johnson DB, Chen Y, Sosman JA, Carson WE III, In G K, Hyngstrom J, Brohl AS, Wada DA, Plaza JA, Sharon E, Patel SP, Sondak VK, Bellasea SL, Kendra KL, Vanderwalde A, Wu MC, Ribas A, Scumpia PO, Campbell KM. Submitted 2026.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

None this cycle.

Submitted Manuscripts

None this cycle.

RADIATION ONCOLOGY COMMITTEE

Published/Accepted Manuscripts

Consensus Radiation Therapy Organ at Risk Constraints for NCTN Trials in Hematologic Malignancies. Sim AJ, Hoppe BS, Ballas LK, Milgrom SA, Terezakis SA, Ha CS, Figura NB, Parikh RR, Grecula JC, Plataras JP, Lo AC, Ryckman J, Flampouri S, Pinnix CC, Kelsey CR. *Journal of the National Cancer Institute*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41965109/>

Submitted Manuscripts

None this cycle.

Future Meeting Dates

SPRING 2027

April 15-17, 2027
San Francisco, CA

FALL 2027

October 14-16, 2027
Chicago, IL

SPRING 2028

March 30-April 1, 2028
San Francisco, CA

FALL 2028

October 5-7, 2028
Chicago, IL

SPRING 2029

April 5-7, 2029
San Francisco, CA

FALL 2029

October 4-6, 2029
Chicago, IL

